

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	3	OCT 19	BEILSTEIN updated with new compounds
NEWS	4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	5	NOV 19	WPIX enhanced with XML display format
NEWS	6	NOV 30	ICSD reloaded with enhancements
NEWS	7	DEC 04	LINPADOCDB now available on STN
NEWS	8	DEC 14	BEILSTEIN pricing structure to change
NEWS	9	DEC 17	USPATOLD added to additional database clusters
NEWS	10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	11	DEC 17	DGENE now includes more than 10 million sequences
NEWS	12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	14	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	16	JAN 02	STN pricing information for 2008 now available
NEWS	17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	19	JAN 28	MARPAT searching enhanced
NEWS	20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	23	FEB 08	STN Express, Version 8.3, now available
NEWS	24	FEB 20	PCI now available as a replacement to DPCI
NEWS	25	FEB 25	IFIREF reloaded with enhancements
NEWS	26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:19:46 ON 04 MAR 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:19:55 ON 04 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAR 2008 HIGHEST RN 1006431-93-1

DICTIONARY FILE UPDATES: 3 MAR 2008 HIGHEST RN 1006431-93-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10535381a.str



```

chain nodes :
17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
5-6
ring bonds :
1-2 1-5 2-3 2-12 3-4 3-14 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 13-14

exact/norm bonds :
1-2 1-5 2-3 2-12 3-4 3-14 4-5 12-13 13-14
exact bonds :
5-6
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :

```

G1:C,H

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 17:CLASS 18:Atom


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:20:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 80 TO ITERATE

100.0% PROCESSED 80 ITERATIONS

32 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1064 TO 2136

PROJECTED ANSWERS: 301 TO 979

L2 32 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 16:20:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1737 TO ITERATE

100.0% PROCESSED 1737 ITERATIONS

745 ANSWERS

SEARCH TIME: 00.00.01

L3 745 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 16:20:22 ON 04 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2008 VOL 148 ISS 10
FILE LAST UPDATED: 3 Mar 2008 (20080303/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full
L4 15 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1170888 CAPLUS

DOCUMENT NUMBER: 148:54984

TITLE: A concise synthesis of quinazolinone TGF- β RI inhibitor through one-pot three-component Suzuki-Miyaura/etherification and imidate-amide rearrangement reactions

AUTHOR(S): Li, Hong-yu; Wang, Yan; McMillen, William T.; Chatterjee, Arindam; Toth, John E.; Mundla, Sreenivasa R.; Voss, Matthew; Boyer, Robert D.; Sawyer, J. Scott

CORPORATE SOURCE: Lilly Corporate Center, Lilly Research Laboratory, Discovery Chemistry Research and Technology, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: Tetrahedron (2007), 63(47), 11763-11770


CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB A simple and efficient synthesis of a dihydropyrrolopyrazole boronic acid intermediate has been developed. Utilization of a three-component Suzuki-Miyaura/etherification with microwave heating led to an advanced pyrrolo[1,2-b]pyrazolyl compound in high yield and with easy purification. Its reaction with methanesulfonyl chloride at room temperature furnished a 1,3 O-N rearranged product, which was postulated to proceed via an intramol. mechanism. The outlined synthesis provided a highly efficient and high-yielding route that was amenable to rapid analog synthesis. The final compds. I (R = pyrrolidinyl, morpholinyl, piperidinyl or azepinyl), were potent at inhibiting TGF- β RI kinase domain with enzymic IC₅₀ values of 93, 95, 123, and 192 nM, resp.

IT 866115-92-6P 866115-94-8P 866115-95-9P


866115-96-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of quinazolinone TGF- β RI inhibitor via one-pot three-component Suzuki-Miyaura/etherification and imidate-amide rearrangement reactions)

RN 866115-92-6 CAPLUS


CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 866115-94-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 866115-95-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 866115-96-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(hexahydro-1H-azepin-1-yl)ethyl]- (CA INDEX NAME)



IT 476473-89-9P 476473-90-2P 705262-42-6P


866115-84-6P 866115-91-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazolinone TGF- β RI inhibitor via one-pot three-component Suzuki-Miyaura/etherification and imidate-amide rearrangement reactions)


RN 476473-89-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476473-90-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 705262-42-6 CAPLUS

CN Boronic acid, B-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 866115-84-6 CAPLUS

CN Ethanol, 2-[[6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-4-quinazolinyl]oxy]- (CA INDEX NAME)



RN 866115-91-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloroethyl)-6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:675680 CAPLUS

DOCUMENT NUMBER: 147:64572

TITLE: Control of intraocular pressure using ALK5 modulation agents

INVENTOR(S): Fleenor, Debra L.; Pang, Iok-Hou; Shepard, Allan R.; Hellberg, Mark R.; Clark, Abbot F.; Klimko, Peter G.

PATENT ASSIGNEE(S): Alcon, Inc., Switz.

SOURCE: PCT Int. Appl., 31pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070866	A2	20070621	WO 2006-US62151	20061215
WO 2007070866	A3	20080103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 2007142376	A1	20070621	US 2006-611312	20061215
PRIORITY APPLN. INFO.:			US 2005-751130P	P 20051216

AB The invention discloses an ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity. The invention also discloses a method for treating glaucoma and controlling intraocular pressure, comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.


IT 476475-07-7 737791-20-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ALK5 modulators for control of intraocular pressure and treatment of glaucoma)


RN 476475-07-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 737791-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:173978 CAPLUS

DOCUMENT NUMBER: 146:229339

TITLE: Preparation of 2-(6-methylpyridin-2-yl)-3-[6-amidoquinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate as a transforming growth factor- β (TGF- β) inhibitor.

INVENTOR(S): Mundla, Sreenivasa Reddy

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 23pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007018818	A1	20070215	WO 2006-US25377	20060629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2005-701641P P 20050722

AB Title compound (I) was prepared I [preparation from 4-aminobenzonitrile, Me vinyl

ketone, Me 6-methyl-2-pyridinecarboxylate, and 1-[(diphenylmethylene)amino]-2-pyrrolidinone given] inhibited TGF- β type I with IC₅₀ = 56 nM.


IT 924898-09-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of methylpyridinylamidoquinolinyl dihydropyrrolopyrazole monohydrate as a transforming growth factor- β inhibitor)


RN 924898-09-9 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, hydrate (1:1) (CA INDEX NAME)




● H₂O

IT 700874-72-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of methylpyridinylamidoquinolinyl dihydropyrrolopyrazole monohydrate as a transforming growth factor- β inhibitor)
 RN 700874-72-2 CAPLUS
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 924898-13-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of methylpyridinylamidoquinolinyl dihydropyrrolopyrazole monohydrate as a transforming growth factor- β inhibitor)
 RN 924898-13-5 CAPLUS
 CN 6-Quinolinecarbonitrile, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:469555 CAPLUS

DOCUMENT NUMBER: 144:488649

TITLE: Pyrrolo[1,2-b]pyrazoles and pyrazolo[1,5-a]pyridines as TGF- β inhibitors, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Diefenbacher, Clive Gideon; Engler, Thomas Albert; Li, Hong-Yu; Malhotra, Sushant; Sawyer, Jason Scott; Wang, Yan

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006052568	A2	20060518	WO 2005-US39554	20051102
WO 2006052568	A3	20060706		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1812450	A2	20070801	EP 2005-815629	20051102
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			

PRIORITY APPLN. INFO.: US 2004-626545P P 20041110
WO 2005-US39554 W 20051102

OTHER SOURCE(S): CASREACT 144:488649; MARPAT 144:488649


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to pyrrolo[1,2-b]pyrazoles and pyrazolo[1,5-a]pyridines of formula I, which are inhibitors of transforming growth factor- β (TGF- β). In compds. I, n is 1 or 2; R1 is H or C1-4 alkyl; and R2 is selected from 1H-pyrrolo[2,3-b]pyridine, 1H-pyrrolo[2,3-c]pyridine, 1H-pyrazolo[3,4-b]pyridine, and 7H-pyrrolo[2,3-d]pyrimidine, all of which are optionally substituted with Ph or C1-4 alkyl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, excipient, or diluent, as well as to the use of the compns. for the treatment of conditions resulting from excessive TGF- β production, such as cancer or fibrosis. Substitution of Me 6-methylpyridinecarboxylate with deprotonated Et acetate and condensation with 1-aminopyrrolidin-2-one gave hydrazone II, which underwent heterocyclization, ester hydrolysis, decarboxylative bromination, and borination to give boronic acid III. Heterocyclocondensation of 2-bromomalonaldehyde with 3-aminopyrazole gave pyrazolopyridine IV, which

underwent Suzuki coupling with III, resulting in the formation of pyrrolopyrazole V. All the compds. of the invention express IC50 values below 1 μ M in an assay for inhibition of TGF- β Type I (RIT204D) receptor kinase domain (no specific data).


IT 887115-57-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of pyrrolopyrazoles and pyrazolopyridines as TGF- β inhibitors)
 RN 887115-57-3 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 887115-58-4P, 1-Methyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-pyrrolo[2,3-b]pyridine 887115-59-5P, 3-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-hydropyrrolo[2,3-b]pyridine 887115-61-9P, 5-[2-[6-Methylpyridin-2-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-hydropyrrolo[3,4-b]pyridine 887115-62-0P, 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-hydropyrrolo[3,4-b]pyridine 887115-63-1P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-hydropyrrolo[2,3-d]pyrimidine 887115-64-2P, 4-[2-[6-Methylpyridin-2-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-hydropyrrolo[2,3-d]pyrimidine 887115-65-3P, 1-Methyl-5-[2-[6-methylpyridin-2-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-pyrazolo[3,4-b]pyridine 887115-68-6P, 1-Phenyl-5-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-pyrazolo[3,4-b]pyridine 887115-69-7P, 1-Methyl-5-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-pyrazolo[3,4-b]pyridine 887115-70-0P, 3-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-hydropyrrolo[2,3-c]pyridine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrrolopyrazoles and pyrazolopyridines as TGF- β inhibitors)
 RN 887115-58-4 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 887115-59-5 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 3-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 887115-61-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 887115-62-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 887115-63-1 CAPLUS
 CN 1H-Pyrrolo[2,3-d]pyrimidine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 887115-64-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 887115-65-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 887115-68-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-phenyl- (CA INDEX NAME)




RN 887115-69-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)



RN 887115-70-0 CAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine, 3-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476473-89-9P, 2-[6-Methyl(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid 476473-90-2P, 3-Bromo-2-[6-methyl(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 700871-79-0P, 2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-ylboronic acid 700871-83-6P, 2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid 700871-84-7P, 3-Bromo-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705262-42-6P, 2-[6-Methylpyridin-2-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-ylboronic acid 887115-60-8P, 1-Benzenesulfonyl-3-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-pyrrolo[2,3-b]pyridine 887115-72-2P, 1-Benzenesulfonyl-3-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H-pyrrolo[2,3-c]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrrolopyrazoles and pyrazolopyridines as TGF- β inhibitors)


RN 476473-89-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476473-90-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(6-methyl-2-pyridinyl)-
(CA INDEX NAME)




RN 700871-79-0 CAPLUS

CN Boronic acid, [5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 700871-83-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(2-pyridinyl)-
(CA INDEX NAME)




RN 700871-84-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX
NAME)




RN 705262-42-6 CAPLUS

CN Boronic acid, B-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-
b]pyrazol-3-yl]- (CA INDEX NAME)




RN 887115-60-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 3-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-(phenylsulfonyl)- (CA INDEX NAME)



RN 887115-72-2 CAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine, 3-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-(phenylsulfonyl)- (CA INDEX NAME)



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:165793 CAPLUS

DOCUMENT NUMBER: 144:390831

TITLE: Dihydropyrrolopyrazole Transforming Growth Factor- β Type I Receptor Kinase Domain Inhibitors: A Novel Benzimidazole Series with Selectivity versus Transforming Growth Factor- β Type II Receptor Kinase and Mixed Lineage Kinase-7

AUTHOR(S): Li, Hong-Yu; Wang, Yan; Heap, Charles R.; King, Chi-Hsin R.; Mundla, Sreenivasa R.; Voss, Matthew; Clawson, David K.; Yan, Lei; Campbell, Robert M.; Anderson, Bryan D.; Wagner, Jill R.; Britt, Karen; Lu, Ku X.; McMillen, William T.; Yingling, Jonathan M.

CORPORATE SOURCE: Discovery Chemistry Research and Technology, Process Chemistry Research, Cancer Research and Lead Optimization Biology, Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: Journal of Medicinal Chemistry (2006), 49(6), 2138-2142
CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:390831

GI




AB Novel dihydropyrrolopyrazole-substituted benzimidazoles were synthesized and evaluated in vitro as inhibitors of transforming growth factor- β type I receptor (TGF- β RI), TGF- β RII, and mixed lineage kinase-7 (MLK-7). These compds. were potent TGF- β RI inhibitors and selective vs. TGF- β RII and MLK-7 kinases. Benzimidazole derivative I was active in an in vivo target (TGF- β RI) inhibition assay.

IT 705263-41-8P 705263-43-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydropyrrolopyrazolylbenzimidazoles as selective inhibitors for transforming growth factor- β type I receptor kinase)


RN 705263-41-8 CAPLUS

CN 1H-Benzimidazole-1-propanol, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 705263-43-0 CAPLUS

CN 1H-Benzimidazole-1-propanol, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 705262-67-5P 705263-00-9P 705263-01-0P
 705263-29-2P 705263-30-5P 705263-31-6P
 705263-32-7P 705263-33-8P 705263-34-9P
 705263-36-1P 705263-45-2P 705263-46-3P
 705263-47-4P 705263-48-5P 705263-49-6P
 705263-50-9P 883214-98-0P 883214-99-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of dihydropyrrolopyrazolylbenzimidazoles as selective inhibitors for transforming growth factor- β type I receptor kinase)


RN 705262-67-5 CAPLUS

CN 1H-Indole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-00-9 CAPLUS

CN 1H-Indole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-01-0 CAPLUS

CN 1H-Indole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-29-2 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 705263-30-5 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-31-6 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-32-7 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-33-8 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-34-9 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (CA INDEX NAME)




RN 705263-36-1 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (CA INDEX NAME)




RN 705263-45-2 CAPLUS

CN 1H-Benzimidazole-1-propanamine, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 705263-46-3 CAPLUS


CN 1H-Benzimidazole-1-propanamine, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-diethyl- (CA INDEX NAME)




RN 705263-47-4 CAPLUS
 CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 705263-48-5 CAPLUS
 CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 705263-49-6 CAPLUS
 CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 705263-50-9 CAPLUS
 CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 883214-98-0 CAPLUS
 CN 1H-Benzimidazole-1-propanamine, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 883214-99-1 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



IT 476473-90-2 700871-79-0 700871-84-7


705262-42-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of dihydropyrrolopyrazolylbenzimidazoles as selective inhibitors for transforming growth factor- β type I receptor kinase)


RN 476473-90-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 700871-79-0 CAPLUS

CN Boronic acid, [5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 700871-84-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)



RN 705262-42-6 CAPLUS

CN Boronic acid, B-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 705263-35-0P 705263-37-2P 705263-42-9P
705263-44-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydropyrrolopyrazolylbenzimidazoles as selective inhibitors for transforming growth factor- β type I receptor kinase)


RN 705263-35-0 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (CA INDEX NAME)




RN 705263-37-2 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (CA INDEX NAME)




RN 705263-42-9 CAPLUS

CN 1H-Benzimidazole-1-propanol, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



RN 705263-44-1 CAPLUS

CN 1H-Benzimidazole-1-propanol, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT:

22

THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1130810 CAPLUS

DOCUMENT NUMBER: 143:403951

TITLE: Gene expression profiling for diagnosis and treatment of leiomyoma, endometriosis, ovarian hyperstimulation syndrome, adhesions, endometrial cancer and other fibrotic disorders

INVENTOR(S): Chegini, Nasser; Luo, Xiaoping; Ding, Li; Williams, R. Stan

PATENT ASSIGNEE(S): University of Florida Research Foundation, Inc., USA

SOURCE: PCT Int. Appl., 202 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005098041	A2	20051020	WO 2005-US10257	20050328
WO 2005098041	A3	20060601		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
US 2004-556546P P 20040326
US 2004-620444P P 20041019
US 2004-636240P P 20041215


AB The present invention provides a method for detecting a fibrotic disorder in a subject by providing a biol. sample obtained from the subject such as endometrium, peritoneal fluid, and/or smooth muscle cells and analyzing the expression of at least one gene that is differentially expressed in the fibrotic disorder of interest and correlating the expression of the genes with the presence or absence of the fibrotic disorder in the subject. The present invention also provides a method and compns. for modulating the expression of genes that are differentially expressed in fibrotic tissues, compared to normal tissues. The present invention also includes arrays, such as microfluidic cards, for detecting differential gene expression in samples of fibrotic tissue. Diseases of the invention include leiomyoma, endometriosis, ovarian hyperstimulation syndrome, adhesions, endometrial cancer and other fibrotic disorders.

IT 476475-07-7, LY580276

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene expression profiling for diagnosis and treatment of leiomyoma, endometriosis, ovarian hyperstimulation syndrome, adhesions, endometrial cancer and other fibrotic disorders)

RN 476475-07-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1075799 CAPLUS

DOCUMENT NUMBER: 143:367315

TITLE: Preparation of fused pyrazole derivatives as TGF-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms

INVENTOR(S): Li, Hong-Yu; Mcmillen, William Thomas; Wang, Yan

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092894	A1	20051006	WO 2005-US4812	20050216
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1723146	A1	20061122	EP 2005-723107	20050216
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 2007155722	A1	20070705	US 2006-597979	20060815
PRIORITY APPLN. INFO.:			US 2004-548910P	P 20040301
			WO 2005-US4812	W 20050216
OTHER SOURCE(S):	CASREACT 143:367315; MARPAT 143:367315			

GI



I



II


AB Title compds. represented by the formula I [wherein R1 = H or alkyl; R2 = (un)substituted 4-quinazolinone-6-yl, 2-quinoxalinone-7-yl or benzo[1,4]oxazin-3-one-6-yl; m = 1-3; and pharmaceutically acceptable salts thereof] were prepared as TGF- β (transforming growth factor- β) signal transduction inhibitors. For example, II was provided in a multi-step synthesis starting from 2-amino-5-iodobenzoic

acid. I showed inhibition of TGF- β type I receptor kinase with IC₅₀ values < 20 μ M. Thus, I and their pharmaceutical compns. are useful as TGF- β signal transduction inhibitors for the treatment of fibrosis and neoplasms (no data).

IT 866115-91-5P, 3-(2-Chloroethyl)-6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3H-quinazolin-4-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrrolo[1,2-b]pyrazole derivs. as TGF- β signal transduction inhibitors for treatment of fibrosis and neoplasms)

RN 866115-91-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-chloroethyl)-6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




IT 866115-86-8P, 3-Methyl-6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3H-quinazolin-4-one 866115-87-9P, 3-Methyl-6-[2-(6-pentylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3H-quinazolin-4-one 866115-88-0P, 1-Methyl-7-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-quinoxalin-2-one 866115-89-1P, 3-Methyl-6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3H-quinazolin-4-one 866115-90-4P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-4H-benzo[1,4]oxazin-3-one 866115-92-6P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(morpholin-4-yl)ethyl]-3H-quinazolin-4-one 866115-93-7P, 3-(2-Dimethylaminoethyl)-6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3H-quinazolin-4-one 866115-94-8P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(piperidin-1-yl)ethyl]-3H-quinazolin-4-one 866115-95-9P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(pyrrolidin-1-yl)ethyl]-3H-quinazolin-4-one 866115-96-0P, 3-[2-(Azepan-1-yl)ethyl]-6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3H-quinazolin-4-one 866115-97-1P 866115-98-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[1,2-b]pyrazole derivs. as TGF- β signal transduction inhibitors for treatment of fibrosis and neoplasms)


RN 866115-86-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-methyl- (CA INDEX NAME)




RN 866115-87-9 CAPLUS

CN 4(3H)-Quinoxalinone, 6-[5,6-dihydro-2-(6-pentyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-methyl- (CA INDEX NAME)




RN 866115-88-0 CAPLUS

CN 2(1H)-Quinoxalinone, 7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 866115-89-1 CAPLUS

CN 4(3H)-Quinoxalinone, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-methyl- (CA INDEX NAME)




RN 866115-90-4 CAPLUS


CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 866115-92-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 866115-93-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 866115-94-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 866115-95-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 866115-96-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-[2-(hexahydro-1H-azepin-1-yl)ethyl]- (CA INDEX NAME)




RN 866115-97-1 CAPLUS
 CN 2(1H)-Quinoxalinone, 7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 866115-98-2 CAPLUS
 CN 2(1H)-Quinoxalinone, 7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



IT 705262-56-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrrolo[1,2-b]pyrazole derivs. as TGF- β signal transduction inhibitors for treatment of fibrosis and neoplasms)
 RN 705262-56-2 CAPLUS
 CN Boronic acid, [5,6-dihydro-2-(6-pentyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




IT 476473-89-9P, 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic Acid 476473-90-2P, 3-Bromo-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 700871-79-0P, [2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]boronic Acid 700871-83-6P, 2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-Carboxylic Acid 700871-84-7P, 3-Bromo-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705262-42-6P, [2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

b]pyrazol-3-yl]boronic Acid 705263-53-2P, 2-[[7-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxalin-2-yl]oxy]ethanol 866115-84-6P, 2-[[6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinazolin-4-yl]oxy]ethanol 866115-85-7P, 1-(2-Chloroethyl)-7-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-quinoxalin-2-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[1,2-b]pyrazole derivs. as TGF- β signal transduction inhibitors for treatment of fibrosis and neoplasms)


RN 476473-89-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476473-90-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 700871-79-0 CAPLUS

CN Boronic acid, [5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 700871-83-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 700871-84-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 705262-42-6 CAPLUS

CN Boronic acid, B-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-53-2 CAPLUS

CN Ethanol, 2-[[7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-quinoxalinyloxy]- (CA INDEX NAME)




RN 866115-84-6 CAPLUS

CN Ethanol, 2-[[6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-4-quinazolinyl]oxy]- (CA INDEX NAME)



RN 866115-85-7 CAPLUS
 CN 2(1H)-Quinoxalinone, 1-(2-chloroethyl)-7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:393830 CAPLUS

DOCUMENT NUMBER: 143:90247

TITLE: Complete Inhibition of Anisomycin and UV Radiation but Not Cytokine Induced JNK and p38 Activation by an Aryl-substituted Dihydropyrrolopyrazole Quinoline and Mixed Lineage Kinase 7 Small Interfering RNA

AUTHOR(S): Wang, Xushan; Mader, Mary M.; Toth, John E.; Yu, Xiaohong; Jin, Najia; Campbell, Robert M.; Smallwood, Jeffrey K.; Christe, Michael E.; Chatterjee, Arindam; Goodson, Theodore, Jr.; Vlahos, Chris J.; Matter, William F.; Bloem, Laura J.

CORPORATE SOURCE: Cardiovascular Discovery Research, Lead Optimization Biology, and Discovery Chemistry Research, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: Journal of Biological Chemistry (2005), 280(19), 19298-19305

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mixed lineage kinase 7 (MLK7) is a mitogen-activated protein kinase kinase kinase (MAPKKK) that activates the pro-apoptotic signaling pathways p38 and JNK. A library of potential kinase inhibitors was screened, and a series of dihydropyrrolopyrazole quinolines was identified as highly potent inhibitors of MLK7 in vitro catalytic activity. Of this series, an aryl-substituted dihydropyrrolopyrazole quinoline (DHP-2) demonstrated an IC50 of 70 nM for inhibition of pJNK formation in COS-7 cell MLK7/JNK cotransfection assays. In stimulated cells, DHP-2 at 200 nM or MLK7 small interfering RNA completely blocked anisomycin and UV induced but had no effect on interleukin-1 β or tumor necrosis factor- α -induced p38 and JNK activation. Addnl., the compound blocked anisomycin and UV-induced apoptosis in COS-7 cells. Heart tissue homogenates from MLK7 transgenic mice treated with DHP-2 at 30 mg/kg had reduced JNK and p38 activation with no apparent effect on ERK activation, demonstrating that this compound can be used to block MLK7-driven MAPK pathway activation in vivo. Taken together, these data demonstrate that MLK7 is the MAPKKK required for modulation of the stress-activated MAPKs downstream of anisomycin and UV stimulation and that DHP-2 can be used to block MLK7 pathway activation in cells as well as in vivo.

IT 700871-96-1 700871-98-3 700872-04-4
700872-67-9 700872-74-8 700873-01-4
700873-31-0 700874-52-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA)


RN 700871-96-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700871-95-0


CMF C26 H20 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700871-98-3 CAPLUS

CN Phenol, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 700871-97-2


CMF C26 H20 N4 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700872-04-4 CAPLUS
CN Benzenamine, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-03-3
CMF C26 H21 N5




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700872-67-9 CAPLUS
CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 700872-74-8 CAPLUS
CN Benzoic acid, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700872-73-7
CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-01-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thienyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-00-3


CMF C25 H20 N4 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700873-31-0 CAPLUS
CN Benzenamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-fluoro- (CA INDEX NAME)



RN 700874-52-8 CAPLUS
CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:78537 CAPLUS
DOCUMENT NUMBER: 142:211379
TITLE: Kinetic Characterization of Novel Pyrazole TGF- β
Receptor I Kinase Inhibitors and Their Blockade of the
Epithelial-Mesenchymal Transition
AUTHOR(S): Peng, Sheng-Bin; Yan, Lei; Xia, Xiaoling; Watkins,
Scott A.; Brooks, Harold B.; Beight, Douglas; Herron,
David K.; Jones, Michael L.; Lampe, John W.; McMillen,
William T.; Mort, Nicholas; Sawyer, J. Scott;
Yingling, Jonathan M.
CORPORATE SOURCE: Lilly Research Laboratories, Lilly Corporate Center,
Indianapolis, IN, 46285, USA
SOURCE: Biochemistry (2005), 44(7), 2293-2304
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Transforming growth factor β (TGF- β) signaling pathways regulate a wide variety of cellular processes including cell proliferation, differentiation, extracellular matrix deposition, development, and apoptosis. TGF- β type-I receptor (T β RI) is the major receptor that triggers several signaling events by activating downstream targets such as the Smad proteins. The intracellular kinase domain of T β RI is essential for its function. In this study, the authors have identified a short phospho-Smad peptide, pSmad3(-3), KVLQTQMGSPSIRCSS(P04)VS as a substrate of T β RI kinase for in vitro kinase assays. This peptide is uniquely phosphorylated by T β RI kinase at the C-terminal serine residue, the phosphorylation site of its parent Smad protein in vivo. Specificity anal. demonstrated that the peptide is phosphorylated by only T β RI and not TGF- β type-II receptor kinase, indicating that the peptide is a physiol. relevant substrate suitable for kinetic anal. and screening of T β RI kinase inhibitors. Utilizing pSmad3(-3) as a substrate, the authors have shown that novel pyrazole compds. are potent inhibitors of T β RI kinase with Ki value as low as 15 nM. Kinetic anal. revealed that these pyrazoles act through the ATP-binding site and are typical ATP competitive inhibitors with tight binding kinetics. More importantly, these compds. were shown to inhibit TGF- β -induced Smad2 phosphorylation in vivo in NMuMg mammary epithelial cells with potency equivalent to the inhibitory activity in the in vitro kinase assay. Cellular selectivity anal. demonstrated that these pyrazoles are capable of inhibiting activin signaling but not bone morphogenic protein or platelet-derived growth factor signal transduction pathways. Further functional anal. revealed that pyrazoles are capable of blocking the TGF- β -induced epithelial-mesenchymal transition in NMuMg cells, a process involved in the progression of cancer, fibrosis, and other human diseases. These pyrazoles provide a foundation for future development of potent and selective T β RI kinase inhibitors to treat human disease.


IT 476475-07-7, LY 580276

RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)

(kinetic characterization of novel pyrazole TGF- β receptor I kinase inhibitors and their blockade of epithelial-mesenchymal transition)

RN 476475-07-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT:

45

THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:493706 CAPLUS

DOCUMENT NUMBER: 141:54330

TITLE: Preparation of novel fused pyrazoles, in particular pyrrolopyrazoles, as transforming growth factor- β (TGF- β) signal transduction inhibitors

INVENTOR(S): Beight, Douglas Wade; Burkholder, Timothy Paul; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Heap, Charles Raymond; King, Chi-Hsin Richard; Li, Hong-Yu; McMillen, William Thomas; Sawyer, Jason Scott; Wang, Yan; Diefenbacher, Clive Gideon; Engler, Thomas Albert; Malhotra, Sushant; Mundla, Sreenivasa Reedy

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050659	A1	20040617	WO 2003-US35969	20031124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003290734	A1	20040623	AU 2003-290734	20031124
EP 1567527	A1	20050831	EP 2003-783318	20031124
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2006058295	A1	20060316	US 2005-535381	20050516
PRIORITY APPLN. INFO.:			US 2002-429982P	P 20021127
			WO 2003-US35969	W 20031124
OTHER SOURCE(S):	MARPAT 141:54330			
GI				




- AB Title compds. I [wherein X = (CH₂)_n; n = 0-4; R₁ = (un)substituted alk(en/yn)yl, alk(enyl/ynyl)oxy, alkylthio, alkylamino, alkanoyl, alkylcarbamoyl, thiophenyl, Ph, etc.; R₂ = (un)substituted thiophenyl, oxazolyl, pyrazinyl, furanyl, imidazo[1,2-a]pyridinyl, benzoimidazolyl, quinoxalinyl, pyrazolo[1,5-a]pyrimidinyl, [1,8]naphthyridinyl, etc.; R₃ = H, alkyl; and their pharmaceutically acceptable salts] were prepared as transforming growth factor- β (TGF- β) signal transduction inhibitors. II was prepared in 5 steps by Claisen condensation of Et pyridin-2-carboxylate, condensation of β -carbonyl ester with 1-aminopyrrolidin-2-one•HCl, cyclization in the presence of NaOEt in toluene, decarboxylative bromination, and Pd-cross coupling of the bromide with thiophene-2-boronic acid. Selected I inhibited the TGF- β type I receptor kinase domain with IC₅₀ values < 20 μ M. I are useful for treating fibroproliferative diseases associated with TGF- β 1 over production
- IT 705263-18-9P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester 705263-35-0P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydropyran-2-yl)oxy]propyl]-1H-benzimidazole 705263-36-1P, 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydropyran-2-yl)oxy]propyl]-1H-benzimidazole 705263-37-2P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydropyran-2-yl)oxy]propyl]-1H-benzimidazole 705263-39-4P, 7-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-quinoxalin-2-one 705263-41-8P, 3-[6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzimidazol-1-yl]propan-1-ol 705263-42-9P, Methanesulfonic Acid 3-[6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzimidazol-1-yl]propyl Ester 705263-43-0P, 3-[6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzimidazol-1-yl]propan-1-ol 705263-74-7P, 2-Chloro-7-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxaline
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
- (TGF- β signal transduction inhibitor; preparation of fused pyrazoles, in particular pyrrolopyrazoles, as TGF- β signal transduction inhibitors)
- RN 705263-18-9 CAPLUS

CN Imidazo[1,2-a]pyridine-2-carboxylic acid, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)




RN 705263-35-0 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (CA INDEX NAME)




RN 705263-36-1 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (CA INDEX NAME)




RN 705263-37-2 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (CA INDEX NAME)




RN 705263-39-4 CAPLUS

CN 2(1H)-Quinoxalinone, 7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-41-8 CAPLUS

CN 1H-Benzimidazole-1-propanol, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-42-9 CAPLUS


CN 1H-Benzimidazole-1-propanol, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



RN 705263-43-0 CAPLUS
 CN 1H-Benzimidazole-1-propanol, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 705263-74-7 CAPLUS
 CN Quinoxaline, 2-chloro-7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 705262-66-4P, 2-(Pyridin-2-yl)-3-(thiophen-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705262-67-5P, 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole 705262-68-6P, 3-(2-Phenyloxazol-5-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705262-70-0P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzo[2,1,3]thiadiazole 705262-73-3P, 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzo[2,1,3]thiadiazole 705262-76-6P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxaline 705262-78-8P, 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxaline 705262-82-4P, 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-imidazo[4,5-b]pyridine 705262-84-6P, 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-imidazo[4,5-c]pyridine 705262-86-8P, 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazole 705262-88-0P, 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]oxazolo[4,5-b]pyridine 705262-89-1P, 2-Dimethylamino-N-[6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,8]naphthyridin-2-yl]acetamide 705262-91-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,8]naphthyridine 705262-92-6P, 2-(Pyridin-2-yl)-3-(imidazo[1,2-a]pyridin-6-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705262-93-7P, 7-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]isoquinoline 705262-94-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]isoquinoline 705262-95-9P, 3-(4-Fluorobenzofuran-7-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705262-96-0P, 2-Methyl-5-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzothiazole 705262-97-1P

, 2-Methyl-5-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzothiazole 705262-98-2P, 3-(4-Fluorobenzofuran-7-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705262-99-3P, 7-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]isoquinoline 705263-00-9P, 1-Methyl-5-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole 705263-01-0P, 1-Methyl-5-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole 705263-02-1P, 3-(Pyrazin-2-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-03-2P, 2-(6-Methylpyridin-2-yl)-3-(pyrazin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-04-3P, 3-(2,3-Dihydrobenzofuran-5-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-05-4P, 3-(Furan-3-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-06-5P, 3-(Furan-3-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-07-6P, 2-(6-Methylpyridin-2-yl)-3-(thiophen-3-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-08-7P, 3-(Benzofuran-5-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-09-8P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyrazolo[1,5-a]pyrimidine 705263-11-2P, 3-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-12-3P, 3-[(Morpholin-4-yl)methyl]-6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine 705263-13-4P, 1-(Morpholin-4-yl)-2-[6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridin-3-yl]ethanone 705263-14-5P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester 705263-16-7P, 705263-17-8P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-3-carboxylic acid (2-dimethylaminoethyl)amide 705263-19-0P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-2-carboxylic acid amide 705263-20-3P, 8-Fluoro-6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine 705263-21-4P, [6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridin-3-yl](1,1,3,3-tetramethylbutyl)amine 705263-22-5P, N-[6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridin-3-yl]acetamide 705263-23-6P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-3-carboxylic acid amide 705263-24-7P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-2-carboxylic Acid (2-Dimethylaminoethyl)amide 705263-25-8P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-3-carboxylic Acid Amide 705263-27-0P, 7-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine 705263-28-1P, 3-(4-Chlorophenyl)-6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine 705263-29-2P, 5-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazole 705263-30-5P, 1-Methyl-6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazole 705263-31-6P, 1-Methyl-6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazole 705263-32-7P, 1-Methyl-5-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazole 705263-33-8P, 1-Methyl-5-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazole 705263-34-9P, 5-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-[(tetrahydropyran-2-yl)oxy]propyl]-1H-benzimidazole 705263-38-3P, 2-[[7-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyrido[2,3-b]pyrazin-2-yl]oxy]ethanol 705263-40-7P, 3-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,5]naphthyridine


705263-44-1P, Methanesulfonic acid 3-[6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzimidazol-1-yl]propyl ester
705263-45-2P, Dimethyl[3-[6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazol-1-yl]propyl]amine
705263-46-3P, Diethyl[3-[6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazol-1-yl]propyl]amine
705263-47-4P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(morpholin-4-yl)propyl]-1H-benzimidazole
705263-48-5P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(pyrrolidin-1-yl)propyl]-1H-benzimidazole
705263-49-6P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(piperidin-1-yl)propyl]-1H-benzimidazole
705263-50-9P, 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzimidazole 705263-51-0P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxaline 705263-52-1P, 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxaline 705263-53-2P, 2-[[7-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxalin-2-yl]oxy]ethanol 705263-54-3P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl][1,6]naphthyridine 705263-55-4P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]isoquinoline 705263-56-5P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzothiazole 705263-57-6P, 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzothiazole 705263-58-7P, [5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzothiazol-2-yl]amine 705263-59-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole 705263-61-2P, 3-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole 705263-63-4P, 3-(2,3-Dihydrobenzofuran-5-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-64-5P, Acetic acid 5-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzofuran-3-yl ester 705263-65-6P, 3-(5-Methoxybenzofuran-3-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-66-7P, 5-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzofuran-2-carboxylic acid 705263-67-8P, 3-(Benzofuran-2-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 705263-68-9P, 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyrazolo[1,5-a]pyrimidine 705263-69-0P, 5-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyrazolo[1,5-a]pyrimidine 705263-71-4P, 8-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,6]naphthyridine 705263-72-5P, 3-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyrazolo[1,5-a]pyrimidine 705263-73-6P, 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,5]naphthyridine 705263-75-8P, Dimethyl[2-[[7-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxalin-2-yl]oxy]ethyl]amine 705263-76-9P, 7-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxaline-2-carboxylic acid amide 705263-77-0P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridine-3-carboxylic acid 705263-78-1P, 2-[6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridin-3-yl]acetamide 705263-79-2P, Dimethyl[2-[[7-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoxalin-2-yl]oxy]propyl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(TGF- β signal transduction inhibitor; preparation of fused pyrazoles, in particular pyrrolopyrazoles, as TGF- β signal transduction inhibitors)


RN 705262-66-4 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(2-pyridinyl)-3-(2-thienyl)- (CA INDEX NAME)




RN 705262-67-5 CAPLUS

CN 1H-Indole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-68-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(2-phenyl-5-oxazolyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 705262-70-0 CAPLUS

CN 2,1,3-Benzothiadiazole, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-73-3 CAPLUS

CN 2,1,3-Benzothiadiazole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-76-6 CAPLUS

CN Quinoxaline, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-78-8 CAPLUS

CN Quinoxaline, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-82-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 705262-84-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 705262-86-8 CAPLUS

CN 1H-Benzimidazole, 2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-88-0 CAPLUS

CN Oxazolo[4,5-b]pyridine, 2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-89-1 CAPLUS

CN Acetamide, N-[6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1,8-naphthyridin-2-yl]-2-(dimethylamino)- (CA INDEX NAME)




RN 705262-91-5 CAPLUS

CN 1,8-Naphthyridine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-92-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-93-7 CAPLUS

CN Isoquinoline, 7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-94-8 CAPLUS

CN Isoquinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-95-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluoro-7-benzofuranyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 705262-96-0 CAPLUS

CN Benzothiazole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-methyl- (CA INDEX NAME)




RN 705262-97-1 CAPLUS

CN Benzothiazole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-methyl- (CA INDEX NAME)




RN 705262-98-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluoro-7-benzofuranyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 705262-99-3 CAPLUS

CN Isoquinoline, 7-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-00-9 CAPLUS

CN 1H-Indole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-01-0 CAPLUS

CN 1H-Indole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-02-1 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-pyrazinyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 705263-03-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-pyrazinyl- (9CI) (CA INDEX NAME)




RN 705263-04-3 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(2,3-dihydro-5-benzofuranyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 705263-05-4 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(3-furanyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 705263-06-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(3-furanyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 705263-07-6 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(3-thienyl)- (CA INDEX NAME)




RN 705263-08-7 CAPLUS
 CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(5-benzofuranyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 705263-09-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 705263-11-2 CAPLUS
 CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 705263-12-3 CAPLUS
 CN Imidazo[1,2-a]pyridine, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-3-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 705263-13-4 CAPLUS

CN Morpholine, 4-[[6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridin-3-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 705263-14-5 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)




RN 705263-16-7 CAPLUS

CN Morpholine, 4-[[7-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridin-2-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 705263-17-8 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxamide, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 705263-19-0 CAPLUS

CN Imidazo[1,2-a]pyridine-2-carboxamide, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-20-3 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)




RN 705263-21-4 CAPLUS


CN Imidazo[1,2-a]pyridin-3-amine, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)




RN 705263-22-5 CAPLUS
 CN Acetamide, N-[6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]imidazo[1,2-a]pyridin-3-yl]- (CA INDEX NAME)




RN 705263-23-6 CAPLUS
 CN Imidazo[1,2-a]pyridine-3-carboxamide, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 705263-24-7 CAPLUS
 CN Imidazo[1,2-a]pyridine-2-carboxamide, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 705263-25-8 CAPLUS
 CN Imidazo[1,2-a]pyridine-3-carboxamide, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-27-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-28-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-(4-chlorophenyl)-6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-29-2 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 705263-30-5 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-31-6 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)




RN 705263-32-7 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)



RN 705263-33-8 CAPLUS


CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)



RN 705263-34-9 CAPLUS


CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-methyl- (CA INDEX NAME)

b]pyrazol-3-yl]-1-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (CA INDEX NAME)




RN 705263-38-3 CAPLUS

CN Ethanol, 2-[[7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyrido[2,3-b]pyrazin-2-yl]oxy]- (CA INDEX NAME)




RN 705263-40-7 CAPLUS

CN 1,5-Naphthyridine, 3-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-44-1 CAPLUS

CN 1H-Benzimidazole-1-propanol, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 705263-45-2 CAPLUS

CN 1H-Benzimidazole-1-propanamine, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 705263-46-3 CAPLUS

CN 1H-Benzimidazole-1-propanamine, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-diethyl- (CA INDEX NAME)




RN 705263-47-4 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 705263-48-5 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 705263-49-6 CAPLUS

CN 1H-Benzimidazole, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 705263-50-9 CAPLUS

CN 1H-Benzimidazole, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 705263-51-0 CAPLUS

CN Quinoxaline, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-52-1 CAPLUS

CN Quinoxaline, 2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-53-2 CAPLUS

CN Ethanol, 2-[[7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-quinoxalinyloxy]- (CA INDEX NAME)




RN 705263-54-3 CAPLUS

CN 1,6-Naphthyridine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-55-4 CAPLUS

CN Isoquinoline, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-56-5 CAPLUS


CN Benzothiazole, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-57-6 CAPLUS
 CN Benzothiazole, 2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-58-7 CAPLUS
 CN 2-Benzothiazolamine, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-59-8 CAPLUS
 CN 1H-Indole, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-61-2 CAPLUS
 CN 1H-Indole, 3-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-63-4 CAPLUS
 CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(2,3-dihydro-5-benzofuranyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 705263-64-5 CAPLUS
 CN 3-Benzofuranol, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 705263-65-6 CAPLUS
 CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(5-methoxy-3-benzofuranyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 705263-66-7 CAPLUS
 CN 2-Benzofurancarboxylic acid, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-67-8 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(2-benzofuranyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 705263-68-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 5-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-69-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 5-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-71-4 CAPLUS

CN 1,6-Naphthyridine, 8-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-72-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-73-6 CAPLUS

CN 1,5-Naphthyridine, 2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-75-8 CAPLUS

CN Ethanamine, 2-[[7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-quinoxalinyloxy]-N,N-dimethyl- (CA INDEX NAME)




RN 705263-76-9 CAPLUS

CN 2-Quinoxalinecarboxamide, 7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-77-0 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705263-78-1 CAPLUS

CN Imidazo[1,2-a]pyridine-3-acetamide, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 705263-79-2 CAPLUS

CN 1-Propanamine, 2-[[7-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-quinoxalinyloxy]-N,N-dimethyl- (CA INDEX NAME)




IT 476473-89-9P, 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid 476473-90-2P, 3-Bromo-2-(6-methyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid

methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole
 700871-79-0P, [2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]boronic acid 700871-83-6P 700871-84-7P
 705262-42-6P, [2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]boronic acid 705262-56-2P 705263-26-9P,
 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]imidazo[1,2-a]pyridine-3-carboxylic Acid Ethyl Ester
 705263-60-1P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]indole-1-carboxylic Acid tert-Butyl Ester
 705263-62-3P, 1-Benzenesulfonyl-3-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of fused pyrazoles, in particular
 pyrrolopyrazoles, as TGF- β signal transduction inhibitors)


RN 476473-89-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(6-methyl-2-
 pyridinyl)- (CA INDEX NAME)




RN 476473-90-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(6-methyl-2-pyridinyl)-
 (CA INDEX NAME)




RN 700871-79-0 CAPLUS

CN Boronic acid, [5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
 (9CI) (CA INDEX NAME)




RN 700871-83-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(2-pyridinyl)-
 (CA INDEX NAME)




RN 700871-84-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 705262-42-6 CAPLUS

CN Boronic acid, B-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 705262-56-2 CAPLUS

CN Boronic acid, [5,6-dihydro-2-(6-pentyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 705263-26-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)




RN 705263-60-1 CAPLUS

CN 1H-Indole-1-carboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 705263-62-3 CAPLUS

CN 1H-Indole, 3-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-(phenylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:467896 CAPLUS
DOCUMENT NUMBER: 141:23528
TITLE: Preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators
INVENTOR(S): Chatterjee, Arindam; Goodson, Theodore, Jr.; Mader, Mary Margaret; Toth, John Eldon
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048383	A1	20040610	WO 2003-US35036	20031112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506799	A1	20040610	CA 2003-2506799	20031112
AU 2003298611	A1	20040618	AU 2003-298611	20031112
EP 1567528	A1	20050831	EP 2003-796362	20031112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006522735	T	20061005	JP 2004-555371	20031112
PRIORITY APPLN. INFO.:			US 2002-428322P	P 20021121
			WO 2003-US35036	W 20031112
OTHER SOURCE(S):	MARPAT 141:23528			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, halo, alkyl; R2 = (un)substituted aryl] are prepared For instance, An appropriately substituted 1-[(2,2-disubstituted)ethylideneamino]pyrrolidin-2-one is cyclized to 7-bromo-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline. This intermediate is coupled to thiophene-2-boronic acid (i-PrOH, K2CO3, (PPh3)4Pd, 80°, 5 h) to give II. Certain compds. I have an IC50 ≤ 10,000 nM for mixed lineage kinase 7 (MLK7). I are useful for the treatment of congestive heart disease.

IT 700872-48-6P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic Acid trifluoroacetate 700872-67-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid 700874-15-3P, [2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]ethyl]carbamic acid tert-butyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase

modulators)


RN 700872-48-6 CAPLUS

CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-47-5


CMF C29 H24 N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700872-67-9 CAPLUS

CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 700874-15-3 CAPLUS

CN Carbamic acid, [2-[[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 700871-90-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-thiophen-2-ylquinoline trifluoroacetate
 700871-92-7P, 7-(4-Methylthiophene-2-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline Trifluoroacetate
 700871-94-9P 700871-96-1P, 7-Phenyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700871-98-3P 700872-00-0P 700872-02-2P
 700872-04-4P 700872-06-6P 700872-08-8P
 700872-10-2P, 7-(3-Chlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-12-4P, 7-(4-Chlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-14-6P, 7-(3-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-16-8P
 , 7-(4-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-18-0P
 700872-20-4P, N-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanesulfonamide trifluoroacetate
 700872-22-6P, 7-(2-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-24-8P, 7-(3-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-26-0P, 7-(4-Ethoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-28-2P, 7-(4-Methoxyphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-30-6P, 7-(4-Fluoro-3-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-32-8P, 7-(4-Fluoro-2-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-34-0P, 7-(4-Bromophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-36-2P
 , 7-(4-Ethylsulfanylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-38-4P,
 7-(4-Methylsulfanylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-40-8P,
 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzonitrile trifluoroacetate 700872-42-0P
 700872-44-2P, 1-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]ethanone trifluoroacetate
 700872-46-4P, 2-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]benzamide trifluoroacetate
 700872-50-0P, 7-(3,5-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-52-2P, 7-(4-Methoxy-3-methylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
 700872-54-4P 700872-56-6P 700872-58-8P
 700872-60-2P, 7-(2-Nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-62-4P
 700872-64-6P, 7-(4-(Methanesulfinyl)phenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate

700872-66-8P, 7-Benzo[1,3]dioxol-5-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700872-68-0P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic Acid trifluoroacetate
700872-70-4P, 7-(3,5-Bis-trifluoromethylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700872-72-6P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate
700872-74-8P, 2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid trifluoroacetate
700872-76-0P, 7-(4-Isobutylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700872-78-2P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenoxy]acetic Acid trifluoroacetate
700872-80-6P, 7-Benzo[b]thiophene-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700872-82-8P, 7-Benzofuran-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-84-0P
, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-3-yl]quinoline trifluoroacetate 700872-86-2P,
7-Furan-3-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-88-4P, 7-(4-Methyl-3-nitrophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-90-8P, 7-(4-Cyclohexylphenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline Trifluoroacetate 700872-92-0P,
7-[4-(Benzo[b]thiophene-3-yl)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700872-93-1P
, 7-(3,4-Dichlorophenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-94-2P, 4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoic acid
700872-95-3P, 3-[4-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid
700872-96-4P, 7-(4-Fluorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-97-5P,
7-(4-Methoxyphenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700872-99-7P, 7-Phenyl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-01-4P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[thiophene-2-yl]quinoline trifluoroacetate 700873-02-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)quinoline
700873-03-6P, 7-(4-Chlorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-05-8P,
7-Furan-2-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-07-0P 700873-09-2P
700873-11-6P 700873-13-8P 700873-15-0P
700873-17-2P 700873-19-4P, 7-Cyclohexyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700873-22-9P 700873-24-1P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]acetic acid trifluoroacetate 700873-26-3P, 7-(4-(Methanesulfonyl)phenyl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-28-5P 700873-30-9P
700873-32-1P 700873-34-3P, 5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]isophthalic acid trifluoroacetate 700873-36-5P 700873-38-7P,
7-(2,2-Dioxo-2,3-dihydro-1H-benzo[c]thiophene-5-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate
700873-40-1P 700873-42-3P 700873-45-6P,
7-(6-Methoxypyridazin-3-yl)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline difluoroacetate 700873-47-8P,

4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[pyrimidin-2-yl]quinoline difluoroacetate 700873-49-0P,
4-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]butyramide trifluoroacetate 700873-51-4P
700873-53-6P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[pyrimidin-5-yl]quinoline difluoroacetate
700873-55-8P 700873-57-0P 700873-59-2P,
5-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]thiophene-2-sulfonic acid amide trifluoroacetate 700873-61-6P
700873-63-8P 700873-64-9P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide
700873-65-0P, 3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide 700873-66-1P,
2-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzenesulfonamide 700873-68-3P 700873-71-8P
700873-73-0P, 7-Pyrazol-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700873-75-2P
700873-76-3P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]piperazine-1-carboxylic acid tert-butyl ester
700873-78-5P, 7-Piperidin-1-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700873-80-9P
700873-81-0P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionic acid methyl ester
700873-83-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]propionamide 700873-85-4P
700873-88-7P 700873-91-2P 700873-93-4P
700873-96-7P 700873-98-9P 700874-01-7P
700874-04-0P 700874-07-3P 700874-09-5P,
7-[4-(2-Methoxyethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-11-9P
, 7-[4-(2-Fluoroethoxy)phenyl]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline trifluoroacetate 700874-14-2P
, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2,2,2-trifluoroethoxy)phenyl]quinoline trifluoroacetate
700874-17-5P, Piperidin-1-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
700874-18-6P, [4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]thiomorpholin-4-ylmethanone
700874-20-0P, Morpholin-4-yl[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
700874-22-2P, N-Carbamoylmethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-23-3P
, N-[2-(Isopropylamino)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-24-4P,
N-[2-(tert-Butylsulfanyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-26-6P,
3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]propionic Acid Ethyl Ester
700874-28-8P, N-(1,1-Dioxotetrahydrothiophene-3-yl)-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-30-2P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]piperidine-1-carboxylic acid tert-butyl ester 700874-32-4P
700874-34-6P, N-(2-(Morpholin-4-yl)ethyl)-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide
700874-36-8P, (1,1-Dioxothiophene-4-yl)[4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]phenyl]methanone
700874-38-0P 700874-40-4P 700874-42-6P,
N,N-Dimethyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-44-8P, 3-[4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzoylamino]propionic acid tert-butyl ester 700874-46-0P,

N-Methyl-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-48-2P, N-[2-(Methanesulfonyl)ethyl]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-50-6P, N-[(Dimethylamino)methylene]-4-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-52-8P, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]benzamide 700874-55-1P 700874-57-3P 700874-59-5P 700874-61-9P 700874-69-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase modulators)


RN 700871-90-5 CAPLUS

CN Quinoline, 7-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-thienyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700871-89-2


CMF C24 H18 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700871-92-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methyl-2-thienyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700871-91-6


CMF C25 H20 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700871-94-9 CAPLUS

CN Acetamide, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700871-93-8


CMF C28 H23 N5 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700871-96-1 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700871-95-0
 CMF C26 H20 N4



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 700871-98-3 CAPLUS
 CN Phenol, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 700871-97-2
 CMF C26 H20 N4 O



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 700872-00-0 CAPLUS

CN Phenol, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 700871-99-4


CMF C26 H20 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-02-2 CAPLUS

CN Phenol, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 700872-01-1

CMF C26 H20 N4 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-04-4 CAPLUS
CN Benzenamine, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-03-3
CMF C26 H21 N5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-06-6 CAPLUS
CN Benzenamine, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700872-05-5
CMF C26 H21 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-08-8 CAPLUS

CN Benzenamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-07-7


CMF C17 H16 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-10-2 CAPLUS


CN Quinoline, 7-(3-chlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX

NAME)

CM 1

CRN 700872-09-9


CMF C26 H19 Cl N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-12-4 CAPLUS

CN Quinoline, 7-(4-chlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-11-3


CMF C26 H19 Cl N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-14-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-13-5


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-16-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-15-7


CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-18-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-17-9


CMF C27 H22 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-20-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-19-1


CMF C27 H23 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-22-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-ethoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-21-5


CMF C28 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-24-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-ethoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-23-7
CMF C28 H24 N4 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-26-0 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-ethoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-25-9
CMF C28 H24 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700872-28-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-27-1


CMF C27 H22 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-30-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluoro-3-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-29-3


CMF C27 H21 F N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-32-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluoro-2-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-31-7


CMF C27 H21 F N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-34-0 CAPLUS

CN Quinoline, 7-(4-bromophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700872-33-9

CMF C26 H19 Br N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-36-2 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(ethylthio)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-35-1
CMF C28 H24 N4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700872-38-4 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(methylthio)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-37-3


CMF C27 H22 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-40-8 CAPLUS

CN Benzonitrile, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-39-5


CMF C27 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-42-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-indol-5-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-41-9


CMF C28 H21 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-44-2 CAPLUS

CN Ethanone, 1-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-43-1


CMF C28 H22 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-46-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 4'-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-45-3


CMF C33 H25 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-50-0 CAPLUS

CN Quinoline, 7-(3,5-dichlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-49-7


CMF C26 H18 Cl2 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-52-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxy-3-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-51-1


CMF C28 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 700872-54-4 CAPLUS


CN Benzenamine, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-

yl]-7-quinolinyl]-2-methyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-53-3


CMF C27 H23 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-56-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-55-5


CMF C25 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-58-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-57-7


CMF C25 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-60-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700872-59-9

CMF C26 H19 N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-62-4 CAPLUS
CN Acetamide, N-[3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-61-3
CMF C28 H23 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700872-64-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(methylsulfinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-63-5


CMF C27 H22 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-66-8 CAPLUS

CN Quinoline, 7-(1,3-benzodioxol-5-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-65-7


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-68-0 CAPLUS

CN Benzoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-67-9


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-70-4 CAPLUS

CN Quinoline, 7-[3,5-bis(trifluoromethyl)phenyl]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-69-1


CMF C28 H18 F6 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-72-6 CAPLUS

CN Benzoic acid, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-71-5


CMF C27 H20 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-74-8 CAPLUS

CN Benzoic acid, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-73-7
CMF C27 H20 N4 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-76-0 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-methylpropyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-75-9
CMF C30 H28 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-78-2 CAPLUS
 CN Acetic acid, [4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-77-1
 CMF C28 H22 N4 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 700872-80-6 CAPLUS
 CN Quinoline, 7-benzo[b]thien-2-yl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700872-79-3
 CMF C28 H20 N4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-82-8 CAPLUS

CN Quinoline, 7-(2-benzofuranyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-81-7


CMF C28 H20 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-84-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-thienyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700872-83-9

CMF C24 H18 N4 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700872-86-2 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-furanyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700872-85-1
CMF C24 H18 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700872-88-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methyl-3-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-87-3


CMF C27 H21 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-90-8 CAPLUS

CN Quinoline, 7-(4-cyclohexylphenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-89-5


CMF C32 H30 N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700872-92-0 CAPLUS

CN Quinoline, 7-(4-benzo[b]thien-3-ylphenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700872-91-9


CMF C34 H24 N4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700872-93-1 CAPLUS

CN Quinoline, 7-(3,4-dichlorophenyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 700872-94-2 CAPLUS

CN Benzoic acid, 4-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700872-95-3 CAPLUS

CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700872-96-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-fluorophenyl)- (CA INDEX NAME)



RN 700872-97-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methoxyphenyl)- (CA INDEX NAME)



RN 700872-99-7 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CRN 700872-98-6
CMF C27 H22 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-01-4 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thienyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-00-3
CMF C25 H20 N4 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700873-02-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-nitrophenyl)- (CA INDEX NAME)



RN 700873-03-6 CAPLUS

CN Quinoline, 7-(4-chlorophenyl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 700873-05-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-furanyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700873-04-7

CMF C24 H18 N4 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-07-0 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-thiazolyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-06-9
CMF C23 H17 N5 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-09-2 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-pyrazinyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-08-1
CMF C24 H18 N6



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-11-6 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-10-5
CMF C25 H19 N5



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700873-13-8 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrrol-2-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-12-7


CMF C24 H19 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-15-0 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-indol-2-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-14-9


CMF C28 H21 N5



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700873-17-2 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrrol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-16-1
 CMF C24 H19 N5



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 700873-19-4 CAPLUS
 CN Quinoline, 7-cyclohexyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700873-18-3
 CMF C26 H26 N4

b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-23-0


CMF C28 H22 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-26-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(methanesulfonyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-25-2


CMF C27 H22 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-28-5 CAPLUS

CN Benzeneethanamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-27-4


CMF C28 H25 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-30-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700873-29-6

CMF C27 H22 N4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-32-1 CAPLUS
CN Benzenamine, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-fluoro-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-31-0
CMF C26 H20 F N5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-34-3 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700873-33-2
CMF C28 H20 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-36-5 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, dimethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-35-4


CMF C30 H24 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 700873-38-7 CAPLUS
 CN Quinoline, 7-(1,3-dihydro-2,2-dioxidobenzo[c]thien-5-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-37-6
 CMF C28 H22 N4 O2 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 700873-40-1 CAPLUS
 CN 2-Pyridinecarboxylic acid, 6-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700873-39-8
 CMF C26 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-42-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(5-fluoro-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-41-2


CMF C25 H18 F N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-45-6 CAPLUS

CN Acetic acid, difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(6-methoxy-3-pyridazinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-44-5


CMF C25 H20 N6 O



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-47-8 CAPLUS

CN Acetic acid, difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-pyrimidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-46-7


CMF C24 H18 N6



CM 2

CRN 381-73-7

CMF C2 H2 F2 O2




RN 700873-49-0 CAPLUS

CN Benzenebutanamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-

b[pyrazol-3-yl]-7-quinolinyll]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-48-9
CMF C30 H27 N5 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-51-4 CAPLUS
CN Acetic acid, difluoro-, compd. with 7-(1H-benzimidazol-2-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-50-3
CMF C27 H20 N6



CM 2


CRN 381-73-7
CMF C2 H2 F2 O2



RN 700873-53-6 CAPLUS
 CN Acetic acid, difluoro-, compd. with 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(5-pyrimidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-52-5
 CMF C24 H18 N6



CM 2


CRN 381-73-7
 CMF C2 H2 F2 O2



RN 700873-55-8 CAPLUS
 CN Benzenamine, 2-chloro-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-54-7
 CMF C26 H20 Cl1 N5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-57-0 CAPLUS
CN Phenol, 2-chloro-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-6-fluoro-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-56-9
CMF C26 H18 Cl F N4 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-59-2 CAPLUS
CN 2-Thiophenesulfonamide, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-58-1
CMF C24 H19 N5 O2 S2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-61-6 CAPLUS
CN Phenol, 5-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2,3-difluoro-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-60-5
CMF C26 H18 F2 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700873-63-8 CAPLUS

CN 2-Benzothiazolamine, 6-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-62-7
CMF C27 H20 N6 S




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-64-9 CAPLUS
CN Benzenesulfonamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-65-0 CAPLUS
CN Benzenesulfonamide, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 700873-66-1 CAPLUS

CN Benzenesulfonamide, 2-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-68-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-imidazol-1-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-67-2


CMF C23 H18 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-71-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-1,2,4-triazol-1-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-70-7


CMF C22 H17 N7



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-73-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-pyrazol-1-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700873-72-9

CMF C23 H18 N6



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-75-2 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1H-1,2,3-triazol-1-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-74-1
CMF C22 H17 N7




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700873-76-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 700873-78-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1-piperidinyl)- (CA INDEX NAME)




RN 700873-80-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 700873-81-0 CAPLUS


CN Benzenepropanoic acid, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (CA INDEX NAME)



RN 700873-83-2 CAPLUS

CN Benzenepropanamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-

b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700873-85-4 CAPLUS

CN Ethanamine, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-N,N-dimethyl-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 700873-84-3


CMF C30 H29 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700873-88-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[2-(4-morpholinyl)ethoxy]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700873-87-6

CMF C32 H31 N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-91-2 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-90-1
CMF C33 H33 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700873-93-4 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-

[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-92-3
CMF C32 H31 N5 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700873-96-7 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(1-piperidinyl)propoxy]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700873-95-6
CMF C34 H35 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700873-98-9 CAPLUS

CN 1-Propanamine, 3-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]phenoxy]-N,N-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700873-97-8


CMF C31 H31 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-01-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(4-morpholinyl)propoxy]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700874-00-6

CMF C33 H33 N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 700874-04-0 CAPLUS
CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 700874-03-9
CMF C33 H33 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700874-07-3 CAPLUS
CN Acetamide, 2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-

yl]-7-quinolinyl]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-06-2


CMF C28 H23 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-09-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-methoxyethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-08-4


CMF C29 H26 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-11-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2-fluoroethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-10-8


CMF C28 H23 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-14-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(2,2,2-trifluoroethoxy)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 700874-13-1


CMF C28 H21 F3 N4 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 700874-17-5 CAPLUS

CN Piperidine, 1-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 700874-18-6 CAPLUS

CN Thiomorpholine, 4-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 700874-20-0 CAPLUS


CN Morpholine, 4-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 700874-22-2 CAPLUS


CN Benzamide, N-(2-amino-2-oxoethyl)-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-

pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 700874-23-3 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-[(1-methylethyl)amino]ethyl]- (CA INDEX NAME)




RN 700874-24-4 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-[(1,1-dimethylethyl)thio]ethyl]- (CA INDEX NAME)




RN 700874-26-6 CAPLUS

CN β -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 700874-28-8 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)



RN 700874-30-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 700874-32-4 CAPLUS


CN L-Lysine, N2-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-N6-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 700874-34-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 700874-36-8 CAPLUS
 CN Thiomorpholine, 4-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 700874-38-0 CAPLUS
 CN D-Cysteine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-S-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 700874-40-4 CAPLUS
 CN L-Glutamic acid, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700874-42-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 700874-44-8 CAPLUS

CN β -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 700874-46-0 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-methyl- (CA INDEX NAME)




RN 700874-48-2 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 700874-50-6 CAPLUS

CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N-[(dimethylamino)methylene]- (9CI) (CA INDEX NAME)



RN 700874-52-8 CAPLUS


CN Benzamide, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)



RN 700874-55-1 CAPLUS


CN Benzamide, N-(2-aminoethyl)-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CRN 700874-54-0
CMF C29 H26 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700874-57-3 CAPLUS
CN Benzamide, N-[(1S)-5-amino-1-methylpentyl]-4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700874-56-2
CMF C33 H34 N6 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 700874-59-5 CAPLUS
CN D-Cysteine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-S-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700874-58-4
CMF C31 H27 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 700874-61-9 CAPLUS
CN L-Glutamic acid, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, mono(trifluoroacetate) (9CI) (CA


INDEX NAME)

CM 1

CRN 700874-60-8

CMF C32 H27 N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 700874-69-7 CAPLUS

CN β -Alanine, N-[4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]benzoyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 700874-68-6

CMF C30 H25 N5 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



```

IT      700872-01-1, 4-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
b]pyrazol-3-yl]quinolin-7-yl]phenol
RL: RCT (Reactant); RACT (Reactant or reagent)
      (preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase
      modulators)
RN      700872-01-1  CAPLUS
CN      Phenol, 4-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-
quinolinyl]- (CA INDEX NAME)

```




IT 476473-88-8P, 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid ethyl ester 476473-89-9P, 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic Acid 476473-90-2P, 3-Bromo-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-61-0P, 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-23-3P, 7-Bromo-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 700871-79-0P, [2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-yl]boronic acid 700871-82-5P, 2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic Acid Ethyl Ester 700871-83-6P, 2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic Acid 700871-84-7P, 3-Bromo-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 700871-85-8P, 2-(6-Methylpyridin-2-yl)-5,6-dihydropyrrolo[1,2-b]pyrazole-3-boronic acid 700873-20-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]quinoline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of substituted pyrrolo[1,2-b]pyrazoles as mixed lineage kinase
modulators)


RN 476473-88-8 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(6-methyl-2-
pyridinyl)-, ethyl ester (CA INDEX NAME)




RN 476473-89-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(6-methyl-2-
pyridinyl)- (CA INDEX NAME)




RN 476473-90-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(6-methyl-2-pyridinyl)-
(CA INDEX NAME)




RN 476474-61-0 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-
b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-23-3 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 700871-79-0 CAPLUS

CN Boronic acid, [5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 700871-82-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(2-pyridinyl)-, ethyl ester (CA INDEX NAME)




RN 700871-83-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 700871-84-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 700871-85-8 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 700873-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:467895 CAPLUS

DOCUMENT NUMBER: 141:23527

TITLE: Preparation of quinolinyl pyrrolopyrazoles as
TGF- β signal transduction inhibitors

INVENTOR(S): Beight, Douglas Wade; Sawyer, Jason Scott; Yingling,
Jonathan Michael

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048382	A1	20040610	WO 2003-US32747	20031110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501322	A1	20040610	CA 2003-2501322	20031110
AU 2003291643	A1	20040618	AU 2003-291643	20031110
BR 2003015337	A	20050816	BR 2003-15337	20031110
EP 1565471	A1	20050824	EP 2003-768531	20031110
EP 1565471	B1	20061004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1714090	A	20051228	CN 2003-80103840	20031110
JP 2006514012	T	20060427	JP 2004-555329	20031110
AT 341550	T	20061015	AT 2003-768531	20031110
NZ 538942	A	20070126	NZ 2003-538942	20031110
ES 2273046	T3	20070501	ES 2003-768531	20031110
US 2006040983	A1	20060223	US 2005-531237	20050413
US 7265225	B2	20070904		
ZA 2005003121	A	20060726	ZA 2005-3121	20050418
MX 2005PA05432	A	20050803	MX 2005-PA5432	20050520
IN 2005KN00943	A	20060421	IN 2005-KN943	20050520
NO 2005003045	A	20050621	NO 2005-3045	20050621
HK 1081948	A1	20070504	HK 2006-102038	20060216
US 2008027102	A1	20080131	US 2007-782659	20070725
PRIORITY APPLN. INFO.:			US 2002-428893P	P 20021122
			WO 2003-US32747	W 20031110
			US 2005-531237	A1 20050413

GI



AB The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (preps. given), was given. The compds. I and II inhibit the TGF- β type I receptor kinase domain with IC₅₀ of <20 μ M, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/US02/11884. The pharmaceutical composition comprising the compound II is claimed.


IT 700874-71-1P 700874-72-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolinyl pyrrolopyrazoles as TGF- β signal transduction inhibitors)


RN 700874-71-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 700874-72-2 CAPLUS


CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-11-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of quinolinyl pyrrolopyrazoles as TGF- β signal
 transduction inhibitors)
 RN 476474-11-0 CAPLUS
 CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-52-9P 476475-44-2P 700874-73-3P
 700874-74-4P 700874-75-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of quinolinyl pyrrolopyrazoles as TGF- β signal
 transduction inhibitors)
 RN 476474-52-9 CAPLUS
 CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476475-44-2 CAPLUS
 CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:465519 CAPLUS

DOCUMENT NUMBER: 141:190720

TITLE: Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines

AUTHOR(S): Li, Hong-Yu; Wang, Yan; Yan, Lei; Campbell, Robert M.; Anderson, Bryan D.; Wagner, Jill R.; Yingling, Jonathan M.

CORPORATE SOURCE: Discovery Chemistry Research, Lilly Corporate Center, A Division of Eli Lilly and Company, Lilly Research Laboratory, Indianapolis, IN, 46285, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3585-3588

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:190720

GI



I



II

AB A novel series of 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines was synthesized and their T β R-1 inhibitory, p38 MAPK inhibitory, and T β R-1-dependent cellular activity were evaluated. Compound I was found to be a highly potent in the enzyme assay and T β R-1-dependent cellular assays. In addition, dimer (II), with a urea linker, shows a similar enzyme and cellular activity despite a bulky substitution.

IT 476477-22-2P 476477-26-6P 476477-37-9P


476477-39-1P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as potent transforming growth factor beta type I receptor kinase domain inhibitor)


RN 476477-22-2 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-26-6 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 476477-37-9 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)



RN 476477-39-1 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)




IT 476477-27-7P 476477-28-8P 476477-29-9P
 476477-32-4P 476477-36-8P 476477-38-0P
 476477-41-5P 476477-94-8P 476477-95-9P
 737765-68-3P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as
 potent transforming growth factor beta type I receptor kinase domain
 inhibitor)


RN 476477-27-7 CAPLUS

CN Propanamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-3-(dimethylamino)- (CA INDEX NAME)




RN 476477-28-8 CAPLUS

CN Methanesulfonamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-29-9 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-32-4 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476477-36-8 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476477-38-0 CAPLUS


CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 476477-41-5 CAPLUS
 CN Urea, N,N'-bis[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-94-8 CAPLUS
 CN 2-Oxazolidinone, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-95-9 CAPLUS
 CN 2-Imidazolidinone, 1-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 737765-68-3 CAPLUS
 CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)



IT 476477-23-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as
 potent transforming growth factor beta type I receptor kinase domain
 inhibitor)
 RN 476477-23-3 CAPLUS
 CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-
 3-yl]- (CA INDEX NAME)




IT 737765-69-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 7-amino 4-pyridinyl-dihydropyrrolopyrazolyl-quinolines as
 potent transforming growth factor beta type I receptor kinase domain
 inhibitor)
 RN 737765-69-4 CAPLUS
 CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]-N-(diphenylmethylene)- (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:465518 CAPLUS
 DOCUMENT NUMBER: 141:190719
 TITLE: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor- β type I receptor kinase domain
 AUTHOR(S): Sawyer, J. Scott; Beight, Douglas W.; Britt, Karen S.; Anderson, Bryan D.; Campbell, Robert M.; Goodson, Theodore; Herron, David K.; Li, Hong-Yu; McMillen, William T.; Mort, Nicholas; Parsons, Stephen; Smith, Edward C. R.; Wagner, Jill R.; Yan, Lei; Zhang, Faming; Yingling, Jonathan M.
 CORPORATE SOURCE: Discovery Chemistry Research and Technology, Lilly Corporate Center, The Lilly Research Laboratories, Indianapolis, IN, 46285, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3581-3584
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:190719
 GI



I




II

AB We have expanded our previously reported series of pyrazole-based inhibitors of the TGF- β type I receptor kinase domain (T β R-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogs. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, Ph substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray anal. of compds. I and II, two potent examples of this new series, with the T β R-I receptor kinase domain.

IT 476475-07-7P
 RL: BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (crystal structure; preparation and activity of aryl- and heteroaryl-substituted dihydropyrrolopyrazoles as inhibitors of the transforming growth factor- β type I receptor kinase domain)

RN 476475-07-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




IT 737791-20-7P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(crystal structure; preparation and activity of aryl- and heteroaryl-substituted dihydropyrrolopyrazoles as inhibitors of the transforming growth factor- β type I receptor kinase domain)

RN 737791-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
(CA INDEX NAME)




IT 476475-08-8P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation and activity of aryl- and heteroaryl-substituted dihydropyrrolopyrazoles as inhibitors of the transforming growth factor- β type I receptor kinase domain)

RN 476475-08-8 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(4-methoxyphenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



IT 476474-33-6P 476474-39-2P 476474-46-1P

476475-05-5P 476475-06-6P 476475-11-3P

476475-12-4P 476475-13-5P 476475-77-1P

476476-39-8P 476477-82-4P 476477-83-5P

737791-21-8P 737791-22-9P 737791-23-0P

737791-24-1P 737791-25-2P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and activity of aryl- and heteroaryl-substituted dihydropyrrolopyrazoles as inhibitors of the transforming growth

factor- β type I receptor kinase domain)


RN 476474-33-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(4-methylphenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-39-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(3,4-difluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-46-1 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-[6-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 476475-05-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476475-06-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(4-methoxyphenyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476475-11-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-methylethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-12-4 CAPLUS

CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-13-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-77-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylthio)- (CA INDEX NAME)




RN 476476-39-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylsulfonyl)- (CA INDEX NAME)




RN 476477-82-4 CAPLUS

CN 2-Pyridinemethanol, 6-[3-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]- (CA INDEX NAME)




RN 476477-83-5 CAPLUS

CN Phenol, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 737791-21-8 CAPLUS

CN Quinoline, 4-[2-(5-fluoro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 737791-22-9 CAPLUS

CN Quinoline, 7-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 737791-23-0 CAPLUS

CN Quinoline, 7-chloro-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 737791-24-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethoxy- (CA INDEX NAME)



RN 737791-25-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:906238 CAPLUS

DOCUMENT NUMBER: 138:4598

TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors

INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paola; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R.

PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.

SOURCE: PCT Int. Appl., 305 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094833	A1	20021128	WO 2002-US11884	20020513
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2446820	A1	20021128	CA 2002-2446820	20020513
AU 2002339268	A1	20021203	AU 2002-339268	20020513
AU 2002339268	B2	20070531		
EP 1397364	A1	20040317	EP 2002-744115	20020513
EP 1397364	B1	20070725		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002009939	A	20040330	BR 2002-9939	20020513
CN 1511157	A	20040707	CN 2002-810508	20020513
JP 2004535404	T	20041125	JP 2002-591506	20020513
HU 2004000451	A2	20041228	HU 2004-451	20020513
NZ 528525	A	20051028	NZ 2002-528525	20020513
CN 1951939	A	20070425	CN 2006-10094674	20020513
AT 368041	T	20070815	AT 2002-744115	20020513
ES 2289116	T3	20080201	ES 2002-744115	20020513
IN 2003KN01359	A	20060317	IN 2003-KN1359	20031022
ZA 2003008546	A	20050131	ZA 2003-8546	20031031
US 2004106604	A1	20040603	US 2003-477111	20031106
US 7087626	B2	20060808		
MX 2003PA10630	A	20040309	MX 2003-PA10630	20031119
NO 2003005193	A	20031121	NO 2003-5193	20031121
HK 1064375	A1	20080206	HK 2004-107054	20040915
PRIORITY APPLN. INFO.:			US 2001-293464P	P 20010524
			CN 2002-810508	A3 20020513
			WO 2002-US11884	W 20020513

OTHER SOURCE(S): MARPAT 138:4598

GI



AB Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; p = 1-8; R3 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared For instance, 1-[[2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.00 μ M for the TGF- β type I receptor.

IT 476477-99-3P, (R)-4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476478-00-9P, (S)-4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)

RN 476477-99-3 CAPLUS

CN Quinoline, 4-[(5R)-5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476478-00-9 CAPLUS


CN Quinoline, 4-[(5S)-5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 476473-79-7P, 7-(3-Chloropropoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-90-2P, 3-Bromo-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476473-92-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid methyl ester 476473-93-5P, 6-[3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridine-2-carboxylic acid dihydrochloride 476473-94-6P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionic acid 476473-95-7P, (S)-6-Benzylloxymethyl-3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-03-0P, [2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methanol 476474-11-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol 476474-25-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid 476474-31-4P, 6-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-37-0P, 4-[5-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-40-5P, 7-Methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-41-6P, 7-Benzylloxy-6-methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-61-0P, 7-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-08-8P, 3-(4-Methoxyphenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476475-13-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-27-1P, 6-[3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridine-2-carboxylic acid methyl ester 476475-29-3P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]acrylic acid methyl ester 476475-43-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid methyl ester 476475-44-2P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid methyl ester 476475-52-2P, 3-[[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propylamine 476475-79-3P, 7-Benzylsulfanyl-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-80-6P, 3-[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]sulfanyl]propan-1-ol 476476-34-3P 476476-36-5P 476476-47-8P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acrylic acid methyl ester 476476-85-4P, N,N-Dimethyl-3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-


pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]benzamide 476477-22-2P
, [4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]amine 476477-39-1P, [4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]carbamic acid 2-hydroxyethyl ester 476477-46-0P, 7-Bromo-4-(4-chloro-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-49-3P, 3-(7-Bromoquinolin-4-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-ol 476477-64-2P, N,N-Dimethyl-3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]thiobenzamide 476477-69-7P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionic acid methyl ester 476477-81-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-amino-1,1-dimethylethyl)amide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)
RN 476473-79-7 CAPLUS
CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476473-90-2 CAPLUS
CN 4H-Pyrrolo[1,2-b]pyrazole, 3-bromo-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476473-92-4 CAPLUS
CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)



RN 476473-93-5 CAPLUS


CN 2-Pyridinecarboxylic acid, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 476473-94-6 CAPLUS


CN 7-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476473-95-7 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-6-[(phenylmethoxy)methyl]-, (6S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-03-0 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)- (CA INDEX NAME)




RN 476474-11-0 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-25-6 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-31-4 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-37-0 CAPLUS

CN Quinoline, 4-[5-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476474-40-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476474-41-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy-7-(phenylmethoxy)- (CA INDEX NAME)




RN 476474-61-0 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-08-8 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(4-methoxyphenyl)-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476475-13-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-27-1 CAPLUS


CN 2-Pyridinecarboxylic acid, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 476475-29-3 CAPLUS
 CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinyl]-, methyl ester (CA INDEX NAME)



RN 476475-43-1 CAPLUS
 CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476475-44-2 CAPLUS
 CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476475-52-2 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476475-79-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(phenylmethyl)thio]- (CA INDEX NAME)




RN 476475-80-6 CAPLUS

CN 1-Propanol, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]thio]- (CA INDEX NAME)




RN 476476-34-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)




RN 476476-36-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-1-oxido-2-pyridinyl)- (CA INDEX NAME)




RN 476476-47-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (CA INDEX NAME)




RN 476476-85-4 CAPLUS

CN Benzamide, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-22-2 CAPLUS

CN 7-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-39-1 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)




RN 476477-46-0 CAPLUS


CN Quinoline, 7-bromo-4-[4-chloro-5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-49-3 CAPLUS
 CN 4H-Pyrrolo[1,2-b]pyrazol-4-ol, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-64-2 CAPLUS
 CN Benzenecarbothioamide, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 476477-69-7 CAPLUS
 CN 7-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)



RN 476477-81-3 CAPLUS
 CN 7-Quinolinecarboxamide, N-(2-amino-1,1-dimethylethyl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476474-32-5P, 3-(Pyridin-4-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-33-6P, 2-(6-Methylpyridin-2-yl)-3-(p-tolyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-35-8P, 2-(6-Methylpyridin-2-yl)-3-(naphthalen-1-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-36-9P, 2-(6-Methylpyridin-2-yl)-3-(pyridin-3-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-38-1P, 3-(4-Fluoronaphthalen-1-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-39-2P, 3-(3,4-Difluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-42-7P, 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-43-8P, 6-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-44-9P, 3-(Naphthalen-2-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-45-0P, 2-(6-Methylpyridin-2-yl)-3-(naphthalen-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-46-1P, 3-(4-Fluorophenyl)-2-(6-trifluoromethylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-51-8P, 4-[5-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-52-9P, 6-Bromo-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-53-0P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-trifluoromethylquinoline 476474-54-1P, 3-(3-Chloro-4-fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-55-2P, 3-(2-Chloro-4-fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-57-4P, 3-(4-Fluoro-3-trifluoromethylphenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-58-5P, 2-(6-Methylpyridin-2-yl)-3-(2,4,5-trifluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-60-9P, 8-Fluoro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-62-1P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-trifluoromethoxyquinoline 476474-63-2P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-trifluoromethylquinoline 476474-64-3P, 7-Methoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-65-4P, 3-(2-Chloropyridin-4-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-66-5P, [3-(7-Bromoquinolin-4-yl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methanol 476474-67-6P, 4-[2-(6-Chloropyridin-2-yl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-68-7P, 4-[2-(6-Ethoxypyridin-2-yl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-69-8P, (S)-4-[6-Benzyloxymethyl-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-chloroquinoline 476474-70-1P, (S)-4-[6-Benzyloxymethyl-2-(6-chloropyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-71-2P, 4-[2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-5-yl]benzoic acid ethyl ester 476474-72-3P, 3-(4-Fluorophenyl)-5,5-dimethyl-2-(6-methylpyridin-2-

yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-73-4P,
 (R)-6-Benzyloxymethyl-3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazole 476474-74-5P,
 5-(4-Chlorophenyl)-3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-
 4H-pyrrolo[1,2-b]pyrazole 476474-90-5P, 4-[5-(4-Fluorophenyl)-2-
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 476474-91-6P, 4-(6-Hydroxymethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-93-8P,
 4-[4-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline 476474-94-9P, 4-[5-Benzyl-2-(pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-96-1P,
 4-(5-Phenethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl)quinoline 476474-97-2P, 4-[5-Phenyl-2-(pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-01-1P,
 2-Chloro-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline 476475-02-2P, 6,8-Dimethoxy-4-[2-(6-methylpyridin-2-
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 476475-03-3P, 4-[2-(6-Bromopyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-04-4P,
 6,8-Dimethoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline 476475-05-5P, 3-(4-Fluorophenyl)-2-(pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 476475-06-6P,
 3-(4-Methoxyphenyl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole
 476475-07-7P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazole 476475-10-2P,
 4-[2-(6-Propylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline 476475-11-3P, 4-[2-(6-Isopropylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-12-4P,
 4-[2-(6-Ethylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline 476475-18-0P, 4-[2-(4-Chloropyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-21-5P,
 4-[5-(3-Methoxyphenyl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinoline 476475-25-9P, 6,7-Difluoro-4-[2-(6-
 methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 476475-26-0P, 6,7-Dimethoxy-4-[2-(6-methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-35-1P,
 6,7-Dichloro-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinoline 476475-36-2P, 3-Benzo[1,3]dioxol-5-yl-2-
 (6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole
 476475-37-3P, 6-(4-Fluorophenyl)-4-[2-(6-methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-38-4P,
 6-Benzo[1,3]dioxol-5-yl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-39-5P,
 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-
 (thiophen-2-yl)quinoline 476475-40-8P, 4-[2-(6-Methylpyridin-2-
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-phenylquinoline
 476475-41-9P, 8-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-42-0P,
 3-Benzo[b]thiophen-2-yl-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazole 476475-45-3P, 4-[2-(6-Methylpyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid
 methyl ester 476475-47-5P, Dimethyl [3-[4-(2-(pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]amine
 476475-48-6P, [3-[6-Methoxy-4-[2-(pyridin-2-yl)-5,6-
 dihydropyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]dimethylamine
 476475-49-7P, ((Cyclopropyl)methyl) propyl [3-[4-(2-(pyridin-2-
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-
 yl]oxy]propyl]amine 476475-50-0P, Diethyl [3-[4-[2-(pyridin-2-
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-
 yl]oxy]propyl]amine 476475-51-1P, Ethyl methyl
 [3-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinolin-7-yl]oxy]propyl]amine 476475-53-3P,

7-[3-(4-Methylpiperazin-1-yl)propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-54-4P, Benzyl methyl
 [3-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-55-5P,
 7-(3-(Piperidin-1-yl)propoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-56-6P,
 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinoline 476475-57-7P,
 7-(3-(Azepan-1-yl)propoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-58-8P, 7-(3-(Imidazol-1-yl)propoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-59-9P, 7-(3-(Pyrazol-1-yl)propoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-60-2P, 1'-[3-[[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl][1,4']bipiperidinyl 476475-61-3P, Cyclopropyl 1-methylpiperidin-4-yl [3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]amine 476475-62-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-[1,2,3-triazol-1-yl]propoxy]quinoline 476475-63-5P, Dimethyl [3-[[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-64-6P, Diethyl [3-[[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-65-7P, (Cyclopropylmethyl) propyl [3-[[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-67-9P, Ethyl methyl [3-[[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476475-69-1P, Dimethyl [2-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]ethyl]amine 476475-71-5P, Diethyl [2-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]ethyl]amine 476475-72-6P, 7-(2-(Piperidin-1-yl)ethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-73-7P, Ethyl methyl [2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]ethyl]amine 476475-74-8P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(2-(pyrrolidin-1-yl)ethoxy)quinoline 476475-75-9P, 7-[2-(4-Methylpiperazin-1-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476475-76-0P, 7-Methylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-77-1P, 7-Ethylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-78-2P, 6-Methylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-81-7P, Dimethyl [2-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]sulfanyl]ethyl]amine 476475-82-8P, Dimethyl [[6-[3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridin-2-yl]methyl]amine 476475-83-9P, 7-(2-Propoxyethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-84-0P, N,N-Dimethyl-N'-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyridin-2-yl]ethane-1,2-diamine 476475-85-1P, N,N-Dimethyl-N'-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyridin-2-yl]propane-1,3-diamine 476475-86-2P, 3-[3-[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]oxazolidin-2-one 476475-87-3P, 1-[3-[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]imidazolidin-2-one 476475-88-4P, 3-[3-[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]-3H-benzoxazol-2-one 476475-89-5P, Dimethyl [2-[[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyridin-2-yl]sulfanyl]ethyl]amine

476475-90-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(pyrrolidin-1-yl)quinoline 476475-91-9P, 2-Phenylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-92-0P, 2-Morpholin-4-yl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-93-1P, 2-Ethylsulfanyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-94-2P, Phenyl [4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-2-yl]amine 476475-95-3P, 2-Methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-96-4P, 2-Ethoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-97-5P, 4-[2-(6-Phenylsulfanylpiperidin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476475-98-6P, Phenyl [6-(3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)pyridin-2-yl]amine 476475-99-7P, 4-[2-[6-(4-Methoxyphenyl)pyridin-2-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-00-3P, 4-[2-(6-Phenylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-01-4P, 4-[2-(6-Morpholin-4-ylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-02-5P, 4-[2-(6-Pyrrolidin-1-ylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-03-6P, 4-[2-(6-Methoxypyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-04-7P, 7-Benzoyloxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-05-8P, 2-[3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]isoindole-1,3-dione 476476-06-9P, 7-(3-Fluoropropoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-07-0P, 7-(3-Chloropropoxy)-6-methoxy-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-08-1P, 7-(3-Chloropropoxy)-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-10-5P, N,N-Diethyl-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-11-6P, (R)-7-[2-(2-Methylpyrrolidin-2-yl)ethoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-12-7P, Dimethyl [4-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyridin-2-yl]oxy]butyl]amine 476476-13-8P, 1-[3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]pyridin-2-yloxy]propyl]pyrrolidin-2-one 476476-14-9P, 7-(1-Methylpiperidin-3-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-15-0P, 7-((3-Dimethylamino-2-methylpropyl)oxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-16-1P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-propoxyquinoline 476476-17-2P, 4-[6-Benzoyloxymethyl-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-18-3P, [[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetic acid methyl ester 476476-19-4P, 7-Isopropoxy-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-20-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(morpholin-4-yl)propoxy]quinoline 476476-21-8P, 4-(6-((Benzoyloxy)methyl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl)quinoline 476476-23-0P, 2-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]acetamide 476476-24-1P, 7-(5-Phenyl[1,2,4]oxadiazol-3-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-25-2P, 7-(2,2-Difluorobenzo[1,3]dioxol-5-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-26-3P, (S)-7-[2-(1-Methylpyrrolidin-2-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476476-27-4P, 5-[[[4-(2-(Pyridin-2-yl)-5,6-dihydro-

4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]methyl]pyrrolidin-2-one
 476476-28-5P, 4-(6-Phenoxymethyl-2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-29-6P,
 4-(6-Methylene-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline 476476-30-9P, 3-(4-Fluorophenyl)-6-methylene-2-(6-
 methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole
 476476-31-0P, 7-((1-Methylpiperidin-2-yl)methoxy)-4-(2-(pyridin-2-
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline hydrochloride
 476476-32-1P 476476-33-2P, 7-[2-(1-Methylpyrrolidin-2-
 yl)ethoxy]-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-
 yl]quinoline hydrochloride 476476-35-4P, 7-Methanesulfonyl-4-[2-
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 476476-38-7P, 6-Methanesulfonyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-39-8P,
 7-Ethanesulfonyl-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-
 3-yl]quinoline 476476-40-1P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(pyrimidine-2-sulfonyl)propoxy]quinoline
 476476-41-2P, 7-[3-((1-Methyl-1H-imidazol-2-yl)sulfonyl)propoxy]-4-
 [2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 476476-42-3P, 7-[3-(4-Chlorobenzenesulfonyl)propoxy]-4-[2-(pyridin-
 2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 476476-43-4P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl)-7-[3-((pyridin-2-yl)methane)sulfonyl]propoxy]quinoline
 476476-44-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl)-7-[3-((pyridin-2-yl)methane)sulfinyl]propoxy]quinoline
 476476-46-7P 476476-48-9P, 3-[4-[2-(6-Methylpyridin-2-
 yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]-1-(piperidin-
 1-yl)propanone 476476-49-0P, N,N-Dimethyl-3-[4-[2-(6-
 methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-
 yl]acrylamide 476476-50-3P, 4-[2-(6-Methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-vinylquinoline
 476476-51-4P, 4-[2-(6-Benzylpyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476476-52-5P,
 7-Benzyl-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-
 3-yl]quinoline 476476-53-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ethyl
 ester 476476-54-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid
 476476-55-8P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acrylic acid 476476-56-9P
 , 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-
 7-carboxylic acid cyclopentylamide 476476-57-0P,
 4-[2-(6-Methylpyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-5-yl]benzoic acid 476476-58-1P, 4-[2-(Pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid
 (2-(morpholin-4-yl)ethyl)amide 476476-59-2P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-
 carboxylic acid [2-(1H-imidazol-4-yl)ethyl]amide 476476-60-5P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-
 carboxylic acid (2-methylaminoethyl)amide 476476-61-6P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-
 carboxylic acid (3-methylaminopropyl)amide 476476-62-7P
 , 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-
 carboxylic acid (2-dimethylaminoethyl)amide 476476-63-8P,
 (4-Methylpiperazin-1-yl)[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl]quinolin-7-yl]methanone 476476-64-9P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-
 carboxylic acid cyclobutylamide 476476-65-0P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-
 carboxylic acid cyclopropylamide 476476-66-1P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-
 carboxylic acid (1-ethylpropyl)amide 476476-67-2P,

4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ethylamide 476476-68-3P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid isobutylamide 476476-69-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid tert-butylamide 476476-70-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid isopropylamide 476476-71-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid propylamide 476476-72-9P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-methylbutyl)amide 476476-73-0P 476476-74-1P 476476-75-2P 476476-76-3P 476476-77-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-4-ylmethyl)amide 476476-78-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-3-ylmethyl)amide 476476-79-6P, 1-(4-Methylpiperazin-1-yl)-2-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]ethanone 476476-81-0P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (pyridin-2-ylmethyl)amide 476476-82-1P, 6-(3-(Quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)pyridine-2-carboxylic acid amide 476476-83-2P, N-(2-Dimethylaminoethyl)-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-84-3P, N-(2-Dimethylaminoethyl)-N-methyl-2-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetamide 476476-86-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid amide 476476-89-8P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid ((2-dimethylaminoethyl)methyl)amide 476476-91-2P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid [[3-(dimethylamino)propyl]methyl]amide 476476-93-4P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid dimethylamide 476476-94-5P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid methylamide 476476-95-6P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid N-(pyridin-2-yl)amide 476476-96-7P, N-(2,2-Dimethylaminoethyl)-N-methyl-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476476-97-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 476476-98-9P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (3-dimethylaminopropyl)amide 476476-99-0P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxylic acid (2-(morpholin-4-yl)ethyl)amide 476477-00-6P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-(piperidinyl)ethyl)amide 476477-01-7P, N-(2-Dimethylaminoethyl)-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-02-8P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (3-(morpholin-4-yl)propyl)amide 476477-03-9P, 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-04-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 476477-05-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid [2-(morpholin-4-yl)ethyl]amide 476477-06-2P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-


carboxylic acid 476477-07-3P 476477-08-4P,
 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-
 carboxylic acid amide 476477-09-5P, 4-(2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid
 (3-methylaminopropyl)amide 476477-10-8P, 4-(2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid
 (2-hydroxyethyl)amide 476477-11-9P 476477-12-0P,
 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-
 carboxylic acid hydroxyamide 476477-13-1P, 4-(2-(Pyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid
 (2-aminoethyl)amide 476477-14-2P, 4-(2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid
 (2-hydroxyethyl)amide 476477-15-3P, 4-[2-(6-Methylpyridin-2-yl)-
 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid
 amide 476477-16-4P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid
 ((2-dimethylaminoethyl)methyl)amide 476477-17-5P,
 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-
 sulfonic acid amide 476477-18-6P, 4-(2-(Pyridin-2-yl)-5,6-
 dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid
 methylamide 476477-19-7P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-
 pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-sulfonic acid dimethylamide
 476477-20-0P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl)quinoline-7-sulfonic acid [3-(dimethylamino)propyl]amide
 476477-21-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazol-3-yl)quinoline-7-sulfonic acid diethylamide 476477-24-4P
 476477-25-5P 476477-26-6P, 2-(Dimethylamino)-N-[4-[2-
 (pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-
 yl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-
 b]pyrazoles as TGF- β signal transduction inhibitors)


RN 476474-32-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(2-pyridinyl)-3-(4-pyridinyl)-
 (CA INDEX NAME)




RN 476474-33-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(4-methylphenyl)-2-(6-methyl-2-
 pyridinyl)- (CA INDEX NAME)




RN 476474-35-8 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(1-naphthalenyl)- (CA INDEX NAME)




RN 476474-36-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(3-pyridinyl)- (CA INDEX NAME)




RN 476474-38-1 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluoro-1-naphthalenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-39-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(3,4-difluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-42-7 CAPLUS

CN Quinoline, 6-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
(CA INDEX NAME)




RN 476474-43-8 CAPLUS

CN Quinoline, 6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-44-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(2-naphthalenyl)-2-(2-pyridinyl)-
(CA INDEX NAME)




RN 476474-45-0 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(2-naphthalenyl)- (CA INDEX NAME)




RN 476474-46-1 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-[6-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)




RN 476474-51-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-5-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-52-9 CAPLUS

CN Quinoline, 6-bromo-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-53-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 476474-54-1 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(3-chloro-4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-55-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(2-chloro-4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-57-4 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-[4-fluoro-3-(trifluoromethyl)phenyl]-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-58-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(2,4,5-trifluorophenyl)- (CA INDEX NAME)




RN 476474-60-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-8-fluoro- (CA INDEX NAME)




RN 476474-62-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 476474-63-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(trifluoromethyl)- (CA INDEX NAME)




RN 476474-64-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-methoxy- (CA INDEX NAME)




RN 476474-65-4 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(2-chloro-4-pyridinyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476474-66-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-67-6 CAPLUS

CN Quinoline, 4-[2-(6-chloro-2-pyridinyl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-68-7 CAPLUS
 CN Quinoline, 4-[2-(6-ethoxy-2-pyridinyl)-5-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-69-8 CAPLUS
 CN Quinoline, 7-chloro-4-[(6S)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-6-[(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-70-1 CAPLUS
 CN Quinoline, 4-[(6S)-2-(6-chloro-2-pyridinyl)-5,6-dihydro-6-[(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-71-2 CAPLUS

CN Benzoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-5-yl]-, ethyl ester (CA INDEX NAME)



RN 476474-72-3 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-5,5-dimethyl-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 476474-73-4 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-6-[(phenylmethoxy)methyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-74-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5-(4-chlorophenyl)-3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476474-90-5 CAPLUS

CN Quinoline, 4-[5-(4-fluorophenyl)-5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-91-6 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(2-pyridinyl)-3-(4-quinolinyl)- (CA INDEX NAME)




RN 476474-93-8 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-4-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476474-94-9 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-5-(phenylmethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-96-1 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-5-(2-phenylethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-97-2 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-5-phenyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-01-1 CAPLUS

CN Quinoline, 2-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-02-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-03-3 CAPLUS

CN Quinoline, 4-[2-(6-bromo-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-04-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,8-dimethoxy- (CA INDEX NAME)




RN 476475-05-5 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476475-06-6 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 5,6-dihydro-3-(4-methoxyphenyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476475-07-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476475-10-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-propyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-11-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-methylethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-12-4 CAPLUS

CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476475-18-0 CAPLUS


CN Quinoline, 4-[2-(4-chloro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476475-21-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-5-(3-methoxyphenyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-25-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,7-difluoro- (CA INDEX NAME)




RN 476475-26-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6,7-dimethoxy- (CA INDEX NAME)




RN 476475-35-1 CAPLUS

CN Quinoline, 6,7-dichloro-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-36-2 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(1,3-benzodioxol-5-yl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 476475-37-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 476475-38-4 CAPLUS

CN Quinoline, 6-(1,3-benzodioxol-5-yl)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476475-39-5 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(2-thienyl)- (CA INDEX NAME)



RN 476475-40-8 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(2-thienyl)- (CA INDEX NAME)

b]pyrazol-3-yl]-6-phenyl- (CA INDEX NAME)




RN 476475-41-9 CAPLUS

CN Quinoline, 8-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-42-0 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-benzo[b]thien-2-yl-5,6-dihydro-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 476475-45-3 CAPLUS


CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)



RN 476475-47-5 CAPLUS


CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-

3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-48-6 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-49-7 CAPLUS

CN Cyclopropanemethanamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-propyl- (CA INDEX NAME)




RN 476475-50-0 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-51-1 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-53-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)




RN 476475-54-4 CAPLUS

CN Benzenemethanamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)




RN 476475-55-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 476475-56-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)




RN 476475-57-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(hexahydro-1H-azepin-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-58-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-imidazol-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-59-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-pyrazol-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-60-2 CAPLUS

CN Quinoline, 7-(3-[1,4'-bipiperidin]-1'-ylpropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476475-61-3 CAPLUS

CN 4-Piperidinamine, N-cyclopropyl-N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1-methyl- (CA INDEX NAME)




RN 476475-62-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(1H-1,2,3-triazol-1-yl)propoxy]- (CA INDEX NAME)




RN 476475-63-5 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-64-6 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-65-7 CAPLUS

CN Cyclopropanemethanamine, N-[3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-N-propyl- (CA INDEX NAME)




RN 476475-67-9 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-69-1 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-71-5 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 476475-72-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 476475-73-7 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 476475-74-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 476475-75-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 476475-76-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(methylthio)- (CA INDEX NAME)




RN 476475-77-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylthio)- (CA INDEX NAME)




RN 476475-78-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(methylthio)- (CA INDEX NAME)




RN 476475-81-7 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]thio]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-82-8 CAPLUS

CN 2-Pyridinemethanamine, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-83-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(2-propoxyethoxy)- (CA INDEX NAME)




RN 476475-84-0 CAPLUS

CN 1,2-Ethanediamine, N'-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 476475-85-1 CAPLUS

CN 1,3-Propanediamine, N'-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 476475-86-2 CAPLUS

CN 2-Oxazolidinone, 3-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-87-3 CAPLUS

CN 2-Imidazolidinone, 1-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-88-4 CAPLUS

CN 2(3H)-Benzoxazolone, 3-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476475-89-5 CAPLUS

CN Ethanamine, 2-[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-pyridinyl]thio]-N,N-dimethyl- (CA INDEX NAME)




RN 476475-90-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 476475-91-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(phenylthio)- (CA INDEX NAME)




RN 476475-92-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(4-morpholinyl)- (CA INDEX NAME)



RN 476475-93-1 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(ethylthio)- (CA INDEX NAME)



RN 476475-94-2 CAPLUS


CN 2-Quinolinamine, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-

yl]-N-phenyl- (CA INDEX NAME)




RN 476475-95-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-methoxy- (CA INDEX NAME)




RN 476475-96-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-ethoxy- (CA INDEX NAME)




RN 476475-97-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(phenylthio)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-phenyl- (CA INDEX NAME)




RN 476475-98-6 CAPLUS

CN 2-Pyridinamine, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]-N-phenyl- (CA INDEX NAME)




RN 476475-99-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(4-methoxyphenyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-00-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-phenyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-01-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(4-morpholinyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-02-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(1-pyrrolidinyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-03-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methoxy-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-04-7 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(phenylmethoxy)- (CA INDEX NAME)




RN 476476-05-8 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)



RN 476476-06-9 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(3-fluoropropoxy)- (CA INDEX NAME)




RN 476476-07-0 CAPLUS
 CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy- (CA INDEX NAME)




RN 476476-08-1 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-10-5 CAPLUS


CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)



RN 476476-11-6 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2R)-2-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-12-7 CAPLUS

CN 1-Butanamine, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-pyridinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476476-13-8 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-pyridinyl]oxy]propyl]- (CA INDEX NAME)




RN 476476-14-9 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(1-methyl-3-piperidinyl)methoxy]- (CA INDEX NAME)



RN 476476-15-0 CAPLUS


CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N,2-trimethyl- (CA INDEX NAME)



RN 476476-16-1 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)

b]pyrazol-3-yl]-7-propoxy- (CA INDEX NAME)




RN 476476-17-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-6-[(phenylmethoxy)methyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-18-3 CAPLUS

CN Acetic acid, [[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 476476-19-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(1-methylethoxy)- (CA INDEX NAME)




RN 476476-20-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)




RN 476476-21-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-[(phenylmethoxy)methyl]-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-6-yl]- (CA INDEX NAME)




RN 476476-23-0 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476476-24-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(5-phenyl-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)



RN 476476-25-2 CAPLUS


CN Quinoline, 7-[(2,2-difluoro-1,3-benzodioxol-5-yl)methoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476476-26-3 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2S)-1-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-27-4 CAPLUS

CN 2-Pyrrolidinone, 5-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]methyl]- (CA INDEX NAME)




RN 476476-28-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-(phenoxyethyl)-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-29-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-methylene-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-30-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole, 3-(4-fluorophenyl)-5,6-dihydro-6-methylene-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 476476-31-0 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(1-methyl-2-piperidinyl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 476476-32-1 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-1-oxido-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)



RN 476476-33-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


NAME)



● HCl


RN 476476-35-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(methylsulfonyl)- (CA INDEX NAME)




RN 476476-38-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-(methylsulfonyl)- (CA INDEX NAME)




RN 476476-39-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(ethylsulfonyl)- (CA INDEX NAME)




RN 476476-40-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(2-pyrimidinylsulfonyl)propoxy]- (CA INDEX NAME)




RN 476476-41-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(1-methyl-1H-imidazol-2-yl)sulfonyl]propoxy]- (CA INDEX NAME)




RN 476476-42-3 CAPLUS

CN Quinoline, 7-[3-[(4-chlorophenyl)sulfonyl]propoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-43-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)sulfonyl]propoxy]- (CA INDEX NAME)




RN 476476-44-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)sulfinyl]propoxy]- (CA INDEX NAME)




RN 476476-46-7 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)




RN 476476-48-9 CAPLUS
 CN Piperidine, 1-[3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)



RN 476476-49-0 CAPLUS
 CN 2-Propenamide, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N,N-dimethyl- (CA INDEX NAME)




RN 476476-50-3 CAPLUS
 CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-ethenyl- (CA INDEX NAME)




RN 476476-51-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-[6-(phenylmethyl)-2-pyridinyl]-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-52-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(phenylmethyl)- (CA INDEX NAME)



RN 476476-53-6 CAPLUS


CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)



RN 476476-54-7 CAPLUS


CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-

pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-55-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476476-56-9 CAPLUS

CN 7-Quinolinecarboxamide, N-cyclopentyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-57-0 CAPLUS


CN Benzoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-5-yl]- (CA INDEX NAME)




RN 476476-58-1 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476476-59-2 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 476476-60-5 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(methylamino)ethyl]- (CA INDEX NAME)




RN 476476-61-6 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(methylamino)propyl]- (CA INDEX NAME)




RN 476476-62-7 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-63-8 CAPLUS

CN Piperazine, 1-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 476476-64-9 CAPLUS

CN 7-Quinolinecarboxamide, N-cyclobutyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-65-0 CAPLUS

CN 7-Quinolinecarboxamide, N-cyclopropyl-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-66-1 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 476476-67-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-ethyl- (CA INDEX NAME)




RN 476476-68-3 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 476476-69-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 476476-70-7 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 476476-71-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-propyl- (CA INDEX NAME)



RN 476476-72-9 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-methylbutyl)- (CA INDEX NAME)



RN 476476-73-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(2S)-2-methylbutyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-74-1 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1S)-1-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-75-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1R)-1-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 476476-76-3 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[(1R)-1,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476476-77-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-78-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-79-6 CAPLUS

CN Piperazine, 1-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 476476-81-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 476476-82-1 CAPLUS

CN 2-Pyridinecarboxamide, 6-[5,6-dihydro-3-(4-quinolinyl)-4H-pyrrolo[1,2-b]pyrazol-2-yl]- (CA INDEX NAME)




RN 476476-83-2 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-84-3 CAPLUS

CN Acetamide, 2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)




RN 476476-86-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476476-89-8 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476476-91-2 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[4-(dimethylamino)butyl]- (CA INDEX NAME)




RN 476476-93-4 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476476-94-5 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476476-95-6 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-2-pyridinyl- (CA INDEX NAME)




RN 476476-96-7 CAPLUS


CN 7-Quinolinepropanamide, N-[2,2-bis(methylamino)ethyl]-4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476476-97-8 CAPLUS
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476476-98-9 CAPLUS
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476476-99-0 CAPLUS
 CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476477-00-6 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 476477-01-7 CAPLUS
 CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 476477-02-8 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 476477-03-9 CAPLUS
 CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-04-0 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476477-05-1 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 476477-06-2 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-07-3 CAPLUS

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, hydrazide (CA INDEX NAME)




RN 476477-08-4 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-09-5 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(methylamino)propyl]- (CA INDEX NAME)




RN 476477-10-8 CAPLUS

CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-11-9 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, hydrazide (CA INDEX NAME)




RN 476477-12-0 CAPLUS

CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-hydroxy- (CA INDEX NAME)




RN 476477-13-1 CAPLUS

CN 7-Quinolinecarboxamide, N-(2-aminoethyl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-14-2 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-15-3 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-16-4 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)



RN 476477-17-5 CAPLUS
 CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-18-6 CAPLUS
 CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-methyl- (CA INDEX NAME)




RN 476477-19-7 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-20-0 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 476477-21-1 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-diethyl- (CA INDEX NAME)




RN 476477-24-4 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 476477-25-5 CAPLUS

CN 7-Quinolinesulfonamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 476477-26-6 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-2-(dimethylamino)- (CA INDEX NAME)




IT 476477-27-7P, 3-Dimethylamino-N-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide
 476477-28-8P, N-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]methanesulfonamide 476477-29-9P,
 N-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acetamide 476477-31-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid
 [2-dimethylamino-1-methylethyl]amide 476477-32-4P,
 N-(2-Dimethylaminoethyl)-N'-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]urea 476477-33-5P,
 N-[3-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]propyl]methanesulfonamide 476477-34-6P,
 1-Methyl-1H-imidazole-4-sulfonic acid [3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]amide
 476477-35-7P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid
 (2-dimethylamino-1-methylethyl)amide 476477-36-8P,
 N-(3-Dimethylaminopropyl)-N'-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]urea 476477-37-9P,
 N-(2-Hydroxyethyl)-N'-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]urea 476477-38-0P,
 [4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]carbamic acid methyl ester 476477-40-4P, [4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]carbamic acid
 2-methoxyethyl ester 476477-41-5P, N,N'-Bis[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]urea
 476477-42-6P, Dimethylcarbamic acid 4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl ester
 476477-43-7P, 7-Bromo-2-isopropyl-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-44-8P,
 2-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]propan-2-ol 476477-45-9P, 7-((3-Chloropropyl)sulfanyl)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-47-1P, 8-Chloro-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol
 476477-48-2P, 8-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol 476477-50-6P,
 7-Bromo-4-[4-methoxy-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-51-7P, [3-(7-Bromoquinolin-4-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-yl]methylamine
 476477-53-9P, 3-(7-Bromoquinolin-4-yl)-2-(pyridin-2-yl)-5,6-dihydropyrrolo[1,2-b]pyrazol-4-one 476477-54-0P,
 3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]benzonitrile 476477-56-2P, 3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]benzamide
 476477-58-4P, 7-(6-Methylpyridazin-3-yloxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-60-8P,
 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-(4-(pyrimidin-2-yl)piperazin-1-yl)butoxy]quinoline 476477-65-3P,

Dimethyl[3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]benzyl]amine 476477-66-4P,
 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-quinolin-2-one 476477-67-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-ol 476477-68-6P,
 6-Methoxy-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-ol 476477-70-0P, 4-[6-Methyl-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-71-1P,
 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]propionic acid methyl ester 476477-72-2P,
 7-Amino-4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-73-3P, N,N-Dimethyl-3-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]propionamide 476477-74-4P, N-[3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]acetamide 476477-75-5P,
 N-Acetyl-N-[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]acetamide 476477-78-8P, Methyl[3-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]propyl]amine 476477-80-2P,
 7-(Piperidin-4-yloxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-82-4P, [6-[3-(4-Fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]pyridin-2-yl]methanol 476477-83-5P, 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]phenol 476477-84-6P,
 7-(1-Methylpyrrolidin-3-ylmethoxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-85-7P,
 7-(1-Methylpiperidin-4-ylmethoxy)-4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476477-86-8P,
 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (2-dimethylamino-1,1-dimethylethyl)amide 476477-87-9P, (S)-[3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methanol 476477-88-0P,
 (R)-[3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methanol 476477-89-1P
 476477-91-5P 476477-94-8P, 3-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxazolidin-2-one 476477-95-9P, 1-[4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]imidazolidin-2-one 476477-96-0P,
 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(pyridin-4-ylmethoxy)quinoline 476477-97-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3-(pyridin-3-yl)propoxy)quinoline 476477-98-2P, 7-(4,5-Dihydro-1H-imidazol-2-yl)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476478-01-0P, 4-[2-(6-Vinylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476478-03-2P,
 3-[4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-6-yl]acrylic acid 476478-04-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid (2-acetylaminioethyl)amide 476478-05-4P, (R)-7-[2-(1-Methylpyrrolidin-2-yl)ethoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476478-06-5P
 476478-07-6P 476478-08-7P 476478-09-8P,
 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)


RN 476477-27-7 CAPLUS

CN Propanamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-3-(dimethylamino)- (CA INDEX NAME)




RN 476477-28-8 CAPLUS

CN Methanesulfonamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-29-9 CAPLUS

CN Acetamide, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-31-3 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1-methylethyl]- (CA INDEX NAME)




RN 476477-32-4 CAPLUS
 CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 476477-33-5 CAPLUS
 CN Methanesulfonamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)



RN 476477-34-6 CAPLUS
 CN 1H-Imidazole-4-sulfonamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1-methyl- (CA INDEX NAME)




RN 476477-35-7 CAPLUS
 CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1-methylethyl]- (CA INDEX NAME)




RN 476477-36-8 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(3-(dimethylamino)propyl)- (CA INDEX NAME)




RN 476477-37-9 CAPLUS

CN Urea, N-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-N'-(2-hydroxyethyl)- (CA INDEX NAME)




RN 476477-38-0 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 476477-40-4 CAPLUS

CN Carbamic acid, [4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 476477-41-5 CAPLUS

CN Urea, N,N'-bis[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-42-6 CAPLUS


CN Carbamic acid, dimethyl-, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl ester (9CI) (CA INDEX NAME)




RN 476477-43-7 CAPLUS
 CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-2-(1-methylethyl)- (CA INDEX NAME)




RN 476477-44-8 CAPLUS
 CN 6-Quinolinemethanol, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- α,α -dimethyl- (CA INDEX NAME)



RN 476477-45-9 CAPLUS
 CN Quinoline, 7-[(3-chloropropyl)thio]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-47-1 CAPLUS
 CN 7-Quinolinol, 8-chloro-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-48-2 CAPLUS

CN 7-Quinolinol, 8-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-50-6 CAPLUS

CN Quinoline, 7-bromo-4-[5,6-dihydro-4-methoxy-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-51-7 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazol-4-amine, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-53-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazol-4-one, 3-(7-bromo-4-quinolinyl)-5,6-dihydro-2-(2-pyridinyl)- (CA INDEX NAME)




RN 476477-54-0 CAPLUS

CN Benzonitrile, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476477-56-2 CAPLUS

CN Benzamide, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (CA INDEX NAME)




RN 476477-58-4 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(6-methyl-3-pyridazinyl)oxy]- (CA INDEX NAME)




RN 476477-60-8 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butoxy]- (CA INDEX NAME)




RN 476477-65-3 CAPLUS

CN Benzenemethanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476477-66-4 CAPLUS

CN 2(1H)-Quinolinone, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-67-5 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-68-6 CAPLUS

CN 7-Quinolinol, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-methoxy- (CA INDEX NAME)




RN 476477-70-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-6-methyl-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-71-1 CAPLUS


CN 6-Quinolinepropanoic acid, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 476477-72-2 CAPLUS
 CN 7-Quinolinamine, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-73-3 CAPLUS
 CN 7-Quinolinepropanamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 476477-74-4 CAPLUS
 CN Acetamide, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476477-75-5 CAPLUS
 CN Acetamide, N-acetyl-N-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-78-8 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-methyl- (CA INDEX NAME)




RN 476477-80-2 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-piperidinyloxy)- (CA INDEX NAME)




RN 476477-82-4 CAPLUS

CN 2-Pyridinemethanol, 6-[3-(4-fluorophenyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]- (CA INDEX NAME)




RN 476477-83-5 CAPLUS

CN Phenol, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476477-84-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(1-methyl-3-pyrrolidinyl)methoxy]- (CA INDEX NAME)




RN 476477-85-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 476477-86-8 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[2-(dimethylamino)-1,1-dimethylethyl]- (CA INDEX NAME)



RN 476477-87-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-, (6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 476477-88-0 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 476477-89-1 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-acetonitrile, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-, (6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 476477-91-5 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole-6-acetonitrile, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 476477-94-8 CAPLUS

CN 2-Oxazolidinone, 3-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-95-9 CAPLUS

CN 2-Imidazolidinone, 1-[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]- (CA INDEX NAME)




RN 476477-96-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-(4-pyridinylmethoxy)- (CA INDEX NAME)




RN 476477-97-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(3-pyridinyl)propoxy]- (CA INDEX NAME)




RN 476477-98-2 CAPLUS

CN Quinoline, 7-(4,5-dihydro-1H-imidazol-2-yl)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-01-0 CAPLUS

CN Quinoline, 4-[2-(6-ethenyl-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-03-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinyl]- (CA INDEX NAME)



RN 476478-04-3 CAPLUS


CN 7-Quinolinecarboxamide, N-[2-(acetylamino)ethyl]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476478-05-4 CAPLUS


CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-[(2R)-1-methyl-2-pyrrolidinyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 476478-06-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(6-methyl-1-oxido-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476478-07-6 CAPLUS

CN Quinoline, 7-(3-chloropropoxy)-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, 1-oxide (CA INDEX NAME)




RN 476478-08-7 CAPLUS

CN 1-Propanamine, 3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1-oxido-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476478-09-8 CAPLUS


CN 7-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




IT 476474-28-9 476476-80-9, [4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]acetic acid
 476477-23-3, 7-Bromo-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476477-79-9
 476477-90-4, (S)-Methanesulfonic acid [3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methyl ester
 476478-02-1, 4-[2-(6-Chloropyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)
 RN 476474-28-9 CAPLUS
 CN Acetic acid, [[2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 476476-80-9 CAPLUS
 CN Acetic acid, [[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 476477-23-3 CAPLUS
 CN Quinoline, 7-bromo-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



RN 476477-79-9 CAPLUS


CN Carbamic acid, [3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 476477-90-4 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-, methanesulfonate (ester), (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 476478-02-1 CAPLUS

CN Quinoline, 4-[2-(6-chloro-2-pyridinyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)



IT 476473-77-5P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(pyrimidin-2-ylsulfanyl)propoxy]quinoline 476473-81-1P 476473-82-2P, 7-[3-(4-Chlorophenylsulfanyl)propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-83-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-[3-(4-(pyrimidin-2-yl)piperazin-1-yl)propoxy]quinoline 476473-86-6P, 7-[3-[4-(2-Methoxyphenyl)piperazin-1-yl]propoxy]-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476473-87-7P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(((pyridin-2-yl)methyl)sulfanyl)propoxy]quinoline 476473-88-8P, 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid ethyl ester 476473-89-9P, 2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid 476473-91-3P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carboxylic acid 476474-00-7P, 4-[2-(6-Chloromethylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline 476474-02-9P, Methanesulfonic acid [2-(pyridin-2-yl)-3-(quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-yl]methyl ester 476474-09-6P, (R)-Methanesulfonic acid 3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-6-ylmethyl ester 476474-10-9P, 4-[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]piperidine-1-carboxylic acid tert-butyl ester 476474-12-1P, (Pyridin-2-yl)[3-[[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]propyl]amine 476474-13-2P, 7-(5-Chloropentyloxy)-4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline 476474-14-3P, 3-[[[4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]methyl]pyrrolidine-1-carboxylic acid benzyl ester 476474-15-4P, Dimethyl [5-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxy]pentyl]amine 476474-16-5P, Methyl [5-[4-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yloxy]pentyl]amine 476474-17-6P, 1,3-Bis[3-[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yloxy]propyl]-1,3-dihydrobenzimidazol-2-one 476474-18-7P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-2-carboxylic acid ethyl ester 476474-24-5P, [2-Methyl-2-[[4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-7-carbonyl]amino]propyl]carbamic acid tert-butyl ester 476474-26-7P, 6-((tert-Butoxycarbonyl)amino)-2-[[4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-7-carbonyl]amino]hexanoic acid methyl ester 476474-27-8P, [4-[2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinolin-7-yl]oxy]acetic acid 476474-29-0P, 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-((tetrahydrofuran-2-yl)methoxy)quinoline 476474-30-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-

b]pyrazoles as TGF- β signal transduction inhibitors)


RN 476473-77-5 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-(2-pyrimidinylthio)propoxy]- (CA INDEX NAME)




RN 476473-81-1 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(1-methyl-1H-imidazol-2-yl)thio]propoxy]- (CA INDEX NAME)




RN 476473-82-2 CAPLUS

CN Quinoline, 7-[3-[(4-chlorophenyl)thio]propoxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476473-83-3 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)




RN 476473-86-6 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)




RN 476473-87-7 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[3-[(2-pyridinylmethyl)thio]propoxy]- (CA INDEX NAME)



RN 476473-88-8 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(6-methyl-2-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 476473-89-9 CAPLUS


CN 4H-Pyrrolo[1,2-b]pyrazole-3-carboxylic acid, 5,6-dihydro-2-(6-methyl-2-

pyridinyl)- (CA INDEX NAME)




RN 476473-91-3 CAPLUS

CN 7-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-00-7 CAPLUS

CN Quinoline, 4-[2-[6-(chloromethyl)-2-pyridinyl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-02-9 CAPLUS

CN 4H-Pyrrolo[1,2-b]pyrazole-6-methanol, 5,6-dihydro-2-(2-pyridinyl)-3-(4-quinolinyl)-, methanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 476474-09-6 CAPLUS
 CN Ethanesulfonic acid, (6R)-3-(4-fluorophenyl)-5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-6-yl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 476474-10-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 476474-12-1 CAPLUS
 CN 2-Pyridinamine, N-[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]- (CA INDEX NAME)




RN 476474-13-2 CAPLUS
 CN Quinoline, 7-[(5-chloropentyl)oxy]-4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (CA INDEX NAME)




RN 476474-14-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]methyl]-, phenylmethyl ester
 (CA INDEX NAME)



RN 476474-15-4 CAPLUS
 CN 1-Pentanamine, 5-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 476474-16-5 CAPLUS
 CN 1-Pentanamine, 5-[[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]-N-methyl- (CA INDEX NAME)




RN 476474-17-6 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-bis[3-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]propyl]-1,3-dihydro- (CA INDEX NAME)




RN 476474-18-7 CAPLUS

CN 2-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)



RN 476474-24-5 CAPLUS

CN Carbamic acid, [2-[[[4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]carbonyl]amino]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 476474-26-7 CAPLUS

CN L-Lysine, N2-[[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-


yl]-7-quinolinyl]carbonyl]-N6-[(1,1-dimethylethoxy)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 476474-27-8 CAPLUS

CN Acetic acid, [[2-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 476474-29-0 CAPLUS

CN Quinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)



RN 476474-30-3 CAPLUS

CN Quinoline, 7,7'-[1,5-pentanediy]bis(oxy)]bis[4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:19:46 ON 04 MAR 2008)

FILE 'REGISTRY' ENTERED AT 16:19:55 ON 04 MAR 2008

L1 STRUCTURE UPLOADED

L2 32 S L1

L3 745 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:20:22 ON 04 MAR 2008

L4 15 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

83.67

262.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-12.00

-12.00

STN INTERNATIONAL LOGOFF AT 16:22:29 ON 04 MAR 2008